AKTX
Akari Therapeutics
$1.37Tn
9.81
-1.90%
-75.98%
Akari Therapeutics develops antibody-drug conjugates (ADCs), which are biologics consisting of antibodies linked to payloads. The company's revenue model is based on the future sale of these biologic products, as well as licensing, milestones, and royalties from biopharmaceutical partners.
LLY
2nd
Eli Lilly
$1.12Tn
1,185.98
+0.14%
+63.24%
The company engages in strategic collaborations and licensing agreements with biotechnology firms to develop and market products, earning revenue through milestone payments, royalties, and profit sharing from these biologic-focused partnerships.
JNJ
2nd
Johnson & Johnson
$655.56Bn
272.03
+0.31%
+49.78%
The company develops and markets biologics, including monoclonal antibodies and bispecific antibodies such as DARZALEX, RYBREVANT, and TALVEY.
ABBV
2nd
AbbVie
$470.94Bn
266.50
+0.84%
+19.42%
The company has a significant business in biologics and biotechnology, specifically with immunology treatments like Skyrizi, Rinvoq, and Humira, which are used to treat autoimmune diseases.
MRK
2nd
Merck
$367.14Bn
148.81
-0.01%
+89.37%
The company develops and delivers biologic therapies and vaccines, which are derived from biological science, as part of its core human health offerings.
AZN
2nd
Astrazeneca
$257.78Bn
166.31
-0.17%
+12.17%
The company develops and commercializes therapies derived from biological science, including monoclonal antibodies like Imfinzi and Enhertu, as well as recombinant proteins and biologics.
AMGN
Amgen
$226.04Bn
418.13
+0.85%
+52.62%
Amgen is explicitly described as a leading independent biotechnology company that researches, develops, and commercializes therapies derived from biological science. Its revenue is generated from the sale of therapeutic medicines such as Enbrel and Repatha, which are biologic products.
GILD
Gilead Sciences
$188.89Bn
152.21
+0.85%
+35.15%
Gilead is a biopharmaceutical company that develops therapies derived from biological science, including monoclonal antibodies and CAR T cell therapies like Yescarta and Tecartus. Its revenue is driven by the sale of these biologic products and royalties from collaborations.
VRTX
Vertex Pharmaceuticals
$133.68Bn
527.67
+0.28%
+33.48%
Vertex is described as a global biotechnology company that develops therapies derived from biological science, including proteins and biologics. Its revenue is derived from the sale of biologic products, collaboration milestone payments, and royalties.
BMY
2nd
Bristol Myers Squibb
$130.49Bn
63.88
+1.59%
+44.69%
The company operates as a biopharmaceutical firm and develops therapies derived from biological science, including monoclonal antibodies and other biologics like Opdivo and Yervoy.
GSK
2nd
Gsk
$107.24Bn
49.70
+0.93%
+20.92%
The company develops and commercializes biologics and vaccines, including respiratory biologics like Nucala and mRNA-based vaccines for flu and COVID-19.
MRNA
Moderna
$78.71Bn
197.28
-0.80%
+678.84%
Moderna is a biotechnology company that researches and commercializes therapies derived from biological science, specifically messenger RNA (mRNA). Its revenue is generated from the sale of biologic products like Spikevax and mRESVIA, as well as collaboration and licensing revenue.
REGN
Regeneron Pharmaceuticals
$77.33Bn
752.25
-4.54%
+34.15%
Regeneron is a biotechnology company that develops and commercializes therapies derived from biological science, specifically using its VelociSuite and Trap technology to produce fully human antibodies and bispecific molecules. Its revenue is driven by the sale of biologic products such as EYLEA, Dupixent, and Libtayo, as well as collaboration and royalty payments.
ARGX
Argenx Se
$60.17Bn
972.25
+1.33%
+35.22%
Argenx is a biopharmaceutical company that develops and commercializes antibody-based therapeutics, such as VYVGART, which is an FcRn inhibitor. Its revenue is derived from the sale of these biologic products and from milestone payments and royalties from collaborations with partners like Zai Lab and AbbVie.
SNY
2nd
Sanofi
$50.22Bn
41.18
+0.17%
-9.79%
The company has a significant biologics portfolio and leverages biological science for therapies in immunology and rare diseases, as evidenced by products like Nexviazyme.
TEVA
2nd
Teva Pharmaceutical Industries
$45.31Bn
38.88
-0.77%
+102.71%
Teva has a biosimilar business offering monoclonal antibodies like rituximab and trastuzumab to hospitals and specialty care providers.
ONC
2nd
BeOne Medicines
$41.48Bn
367.00
+1.70%
+10.27%
The company develops therapies derived from biological science, including antibody drug conjugates and bispecific therapies, which are characteristic of biotechnology.
ALNY
Alnylam Pharmaceuticals
$34.15Bn
255.36
-0.23%
-42.94%
Alnylam is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically RNAi therapeutics consisting of small interfering RNA (siRNA). Its revenue is generated from the sale of biologic products such as AMVUTTRA, ONPATTRO, and GIVLAARI, as well as collaboration payments and royalties from partners like Novartis and Sanofi.
BIIB
Biogen
$33.79Bn
228.69
+0.48%
+65.10%
Biogen is a biopharmaceutical company that researches and commercializes therapies derived from biological science, such as monoclonal antibodies and recombinant proteins. Its revenue is driven by biologic products like SPINRAZA for spinal muscular atrophy and LEQEMBI for Alzheimer's disease.
ROIV
Roivant Sciences
$26.72Bn
36.98
+3.30%
+144.90%
Roivant is a biopharmaceutical company that develops therapies derived from biological science, specifically monoclonal antibodies like IMVT 1402 and batoclimab. Its revenue model is based on biologic product development, collaboration milestones, and royalties from partners such as HanAll and Bayer.
INSM
Insmed
$25.69Bn
117.67
-0.14%
-16.93%
Insmed is a biopharmaceutical company that develops therapies derived from biological science, including the monoclonal antibody INS1148 and the Pulmovance liposomal platform used for ARIKAYCE. Its revenue is derived from the sale of these biologic-based products and potential milestone payments.
INCY
2nd
Incyte
$25.09Bn
124.82
+0.75%
+48.79%
The company develops and commercializes biologic therapies, including MONJUVI (tafasitamab-cxix) and NIKTIMVO (axatilimab-csfr), and leverages a proprietary discovery platform that integrates biologics.
BNTX
BioNTech SE
$25.06Bn
99.08
+0.57%
+1.00%
BioNTech is a biotechnology company that researches and commercializes therapies derived from biological science, specifically leveraging messenger RNA (mRNA) technology and protein-based therapeutics. Its revenue is derived from the sale of the mRNA-based COVID-19 vaccine Comirnaty and significant collaboration and milestone payments from partners like Pfizer and Bristol Myers Squibb.
ZBH
2nd
Zimmer Biomet Holdings
$17.47Bn
91.61
+0.65%
-6.79%
The company's product portfolio explicitly includes biologics, which are therapies derived from biological science used in musculoskeletal health.
JAZZ
2nd
Jazz Pharmaceuticals
$15.47Bn
238.28
+0.14%
+84.68%
The company describes itself as a biopharmaceutical company and utilizes biological science for its oncology pipeline, including the licensing of assets like zanidatamab and the development of multi-asset pipelines for rare cancers.
MDGL
Madrigal Pharmaceuticals
$15.07Bn
517.04
+0.09%
+16.69%
Madrigal Pharmaceuticals is a biopharmaceutical company that developed Rezdiffra (resmetirom), a thyroid hormone receptor beta agonist, and maintains a pipeline of biologics including GLP-1 receptor agonists and siRNA programs. Its revenue is derived from the sale of these biology-based therapies for the treatment of MASH.
EXEL
2nd
Exelixis
$14.53Bn
58.37
+0.36%
+43.87%
The company develops biotherapeutic candidates, including antibody-drug conjugates and bispecific antibodies, which are biology-based therapies. It earns revenue through collaboration agreements and milestones related to these biotherapeutic pipelines.
NBIX
2nd
Neurocrine Biosciences
$14.27Bn
140.44
+1.47%
+0.12%
The company maintains a deep pipeline of therapies derived from biological science, specifically mentioning the development of proteins, antibodies, and peptides for conditions like major depressive disorder and schizophrenia.
ASND
Ascendis Pharma A
$14.26Bn
230.05
+1.97%
+20.07%
Ascendis Pharma is a biopharmaceutical company that uses its proprietary TransCon technology platform to develop therapies derived from biological science, such as SKYTROFA for growth hormone deficiency. Its revenue is generated from the sale of these biologic products and through collaboration milestone payments and royalties.
BBIO
BridgeBio Pharma
$13.01Bn
66.61
+1.59%
+28.19%
BridgeBio is a biopharmaceutical company that develops therapies derived from biological science to treat genetic diseases, such as acoramidis for ATTR-CM and infigratinib for achondroplasia. Its revenue model includes net product sales of Attruby, as well as milestone payments and royalties from collaborations with Bayer and Alexion.
HALO
Halozyme Therapeutics
$12.87Bn
112.89
-0.89%
+54.03%
Halozyme is a biopharmaceutical company that develops therapies and delivery platforms derived from biological science, specifically using recombinant human hyaluronidase (rHuPH20). Its revenue model is based on biologic product sales, licensing fees, milestone payments, and royalties from partners like Roche and Pfizer.
SMMT
Summit Therapeutics
$12.28Bn
15.48
-0.83%
-26.84%
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, which is described as a bispecific antibody. Its revenue model is based on licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
KNSA
Kiniksa Pharmaceuticals International
$11.87Bn
76.10
+1.36%
+96.29%
Kiniksa is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies and cytokine traps like ARCALYST. Its revenue is derived from the sale of these biologic products, as well as milestone payments and royalties from licensing partnerships.
BMRN
Biomarin Pharmaceutical
$11.51Bn
59.46
-1.33%
+10.07%
BioMarin is a biotechnology company that develops and commercializes therapies derived from biological science, specifically enzyme replacement therapies like VIMIZIM and NAGLAZYME for lysosomal storage disorders. Its revenue is driven by the sale of these biologic products and its focus on genetic medicine.
RDY
2nd
Dr Reddys Laboratories
$10.44Bn
12.51
+2.04%
-10.45%
The company operates a biotechnology subsidiary, Aurigene Oncology Limited, which discovers and develops novel therapeutic candidates in oncology and inflammation, and it develops biosimilars within its generics segment.
APGE
Apogee Therapeutics
$10.18Bn
135.07
+0.83%
—
Apogee Therapeutics is a clinical-stage biotechnology company developing biologics, specifically antibody programs targeting IL-13, OX40L, TSLP, and IL-4Rα. Its product candidates, such as APG777 and APG279, are derived from biological science and advanced antibody engineering.
AXSM
2nd
Axsome Therapeutics
$10.14Bn
193.89
-0.62%
+64.84%
The company maintains a deep pipeline of investigational candidates and utilizes proprietary medicinal chemistry and formulation technologies to develop therapies for neurological and psychiatric disorders, which aligns with biotechnology-focused drug development.
GMED
2nd
Globus Medical
$10.04Bn
74.77
+0.32%
+32.52%
The company sells biologics, including allografts and synthetic bone graft substitutes, which are biological therapies used to promote fusion in musculoskeletal procedures.
ARWR
Arrowhead Pharmaceuticals
$9.24Bn
65.46
-0.70%
+93.78%
Arrowhead Pharmaceuticals researches and commercializes therapies derived from biological science, specifically using RNA interference (RNAi) and siRNA triggers to silence genes. Its revenue is generated from the sale of its biologic product REDEMPLO and through collaboration payments and royalties from partners like Amgen and Takeda.
PTGX
Protagonist Therapeutics
$9.21Bn
142.44
+0.41%
+118.67%
Protagonist Therapeutics is a biotechnology company that researches and develops peptide-based therapeutics, including oral and injectable peptides for inflammatory, immunologic, and metabolic diseases. Its revenue model consists of collaboration agreements, upfront payments, and milestone payments from partners like Janssen Biotech and Takeda Pharmaceuticals.
IBRX
ImmunityBio
$8.97Bn
8.52
+0.95%
+231.52%
ImmunityBio is a biotechnology company that develops and commercializes therapies derived from biological science, specifically its lead biologic product ANKTIVA, an IL-15 receptor superagonist. The company generates revenue from the commercial sale of this biologic product for the treatment of BCG-unresponsive NMIBC CIS.
TGTX
Tg Therapeutics
$8.60Bn
56.19
-2.16%
+52.57%
TG Therapeutics is a biotechnology company that commercializes BRIUMVI, an anti-CD20 monoclonal antibody, and develops other biologics. Its revenue is derived from the sale of this biologic product and milestone payments from collaborations.
PCVX
Vaxcyte
$8.44Bn
58.27
+3.66%
+68.17%
Vaxcyte is a clinical-stage biotechnology company developing vaccines using its XpressCF cell-free protein synthesis platform to produce complex antigens. Its revenue model currently consists of research grants, collaboration funding, and potential milestone payments and royalties, which is characteristic of H-02.
PRAX
Praxis Precision Medicines
$7.97Bn
285.65
+1.73%
+445.34%
Praxis is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically antisense oligonucleotides (ASOs) via its Solidus platform. Its revenue model relies on collaboration, milestone payments, and royalties, which is characteristic of biotechnology developers.
ABVX
Abivax
$7.61Bn
96.85
+6.36%
+16.22%
Abivax is a clinical-stage biotechnology company focused on discovering and developing therapeutics for chronic inflammatory diseases, specifically ulcerative colitis and Crohn's disease. Its revenue currently comes from research collaborations, licensing agreements, and grant funding, which is characteristic of the H-02 biotechnology classification.
SYRE
Spyre Therapeutics
$7.56Bn
85.79
+0.12%
+424.39%
Spyre Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies targeting α4β7, TL1A, and IL23. Its revenue model currently relies on collaboration and licensing arrangements, such as those with Paragon, which include milestone payments and royalties.
IONS
Ionis Pharmaceuticals
$7.55Bn
45.57
+2.40%
-28.96%
Ionis is a biotechnology company that develops RNA-targeted medicines using proprietary antisense technology to modify gene expression. Its revenue is derived from the sale of biologic-based products like SPINRAZA and QALSODY, as well as royalties and milestone payments from collaborations.
GPCR
2nd
Structure Therapeutics
$7.49Bn
35.06
-2.42%
+38.58%
The company operates as a clinical-stage developer that generates revenue through upfront payments, milestone payments, and royalties from strategic collaborations, such as its agreements with Schrödinger and Genentech/Roche.
IMVT
Immunovant
$6.91Bn
33.49
+0.57%
+108.53%
Immunovant is a clinical-stage biotechnology company developing therapies derived from biological science, specifically fully human monoclonal antibodies (IMVT-1402 and batoclimab). Its core business is the research and development of these biologics to treat autoimmune diseases.
RYTM
Rhythm Pharmaceuticals
$6.78Bn
98.56
-0.10%
-2.07%
Rhythm Pharmaceuticals is a biopharmaceutical company that develops therapies derived from biological science, specifically melanocortin-4 receptor agonists like setmelanotide (IMCIVREE). Its revenue is generated from the sale of these biologic products and through collaboration, milestone, and royalty payments from partners like Ipsen and LG Chem.
BLRX
BioLineRx
$6.34Bn
2.43
-6.18%
-35.37%
BioLineRx is a biopharmaceutical company that researches and develops therapies derived from biological science, such as motixafortide (a CXCR4 antagonist) for stem-cell mobilization and oncology. Its revenue model is based on biologic product licensing, milestone payments, and royalties from partners like Ayrmid and Gloria.
LGND
Ligand Pharmaceuticals
$6.26Bn
314.10
+4.17%
+81.42%
Ligand is a biopharmaceutical company that develops and licenses biological platform technologies like Captisol and NITRICIL. Its revenue is primarily derived from royalties on biologic products such as Kyprolis and Qarziba, as well as milestone payments from biotechnology development programs.
CGON
CG Oncology
$6.15Bn
69.61
+3.66%
+78.12%
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an oncolytic immunotherapy derived from biological science. Its current revenue is generated through collaboration and milestone payments from partners like Kissei Pharmaceutical and Lepu Biotech.
SRRK
Scholar Rock Holding
$5.97Bn
49.13
+1.03%
+28.08%
Scholar Rock is a biopharmaceutical company that researches and develops therapies derived from biological science, specifically monoclonal antibodies like apitegromab and SRK 439. Its current revenue is derived from collaboration and milestone payments from partners such as Gilead, which is characteristic of clinical-stage biotechnology developers.
MIRM
Mirum Pharmaceuticals
$5.70Bn
87.96
-1.94%
+20.74%
Mirum Pharmaceuticals is a biopharmaceutical company that researches and commercializes therapies for rare diseases, such as Livmarli and Cholbam. Its revenue is derived from the sale of these biologic-based or specialized medicines, as well as milestone payments and royalties from collaborative agreements.
KOD
Kodiak Sciences
$5.65Bn
89.92
+177.96%
+468.75%
Kodiak Sciences develops therapies derived from biological science, specifically using an Antibody Biopolymer Conjugate (ABC) platform to create monoclonal antibodies and bispecific proteins like tarcocimab tedromer (Zenkuda) and KSI-501. The company is a clinical-stage developer focusing on biology-based drug discovery for retinal diseases.
PTCT
Ptc Therapeutics
$5.50Bn
65.95
+5.23%
+8.74%
PTC Therapeutics is a biopharmaceutical company that develops and commercializes therapies derived from biological science for rare diseases. Its revenue is generated from the sale of biologic-based products such as Evrysdi for spinal muscular atrophy and Upstaza for aromatic L-amino decarboxylase deficiency.
COGT
Cogent Biosciences
$5.47Bn
31.86
-1.39%
+125.48%
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies derived from biological science, such as the tyrosine kinase inhibitor bezuclastinib. Its revenue model currently relies on licensing agreements, milestone payments, and potential future royalties from its lead assets.
ORKA
Oruka Therapeutics
$5.29Bn
84.19
-0.32%
+336.44%
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, such as ORKA 001 and ORKA 002, which are biologics. Its revenue model is based on the future commercialization of these biological products and potential collaboration or licensing payments.
DBVT
DBV Technologies
$5.05Bn
11.64
+0.69%
+27.35%
DBV Technologies is a biopharmaceutical company developing therapies derived from biological science, specifically epicutaneous immunotherapy (EPIT) using the Viaskin patch for peanut and cow's milk allergies. Its revenue model currently relies on collaboration agreements, licensing, and milestone payments from partners like Nestlé Health Science.
GRFS
Grifols
$5.04Bn
7.41
+0.82%
-25.38%
Grifols is a global producer of plasma derivatives, manufacturing biologic therapies such as immunoglobulins, albumin, and clotting factors (Factor VIII and IX). These are recombinant or plasma-derived proteins, which falls squarely under the biotechnology classification for therapies derived from biological science.
IOVA
2nd
Iovance Biotherapeutics
$4.98Bn
10.99
-0.09%
+392.83%
The company markets Proleukin, an interleukin 2 product, which is a recombinant protein/cytokine therapy used in oncology indications and as part of the Amtagvi regimen.
ERAS
Erasca
$4.42Bn
14.13
-0.84%
+569.67%
Erasca is a clinical-stage biotechnology company developing therapies derived from biological science, specifically mentioning a biparatopic antibody candidate (ERAS 12) and a modality agnostic strategy including large molecule antibodies. Its revenue model currently relies on licensing agreements, milestone payments, and collaborations typical of biotech developers.
ABCL
AbCellera Biologics
$4.27Bn
13.92
+9.61%
+185.83%
AbCellera is a clinical-stage biotechnology company that researches and develops antibody medicines, including multispecific formats and antibody-drug conjugates. Its revenue model is based on biologic-focused partnership payments, milestones, and royalties from collaborators like Eli Lilly and Regeneron.
TNGX
Tango Therapeutics
$4.09Bn
24.30
-2.49%
+187.91%
Tango Therapeutics is a biotechnology company that researches and develops therapies derived from biological science, specifically using synthetic lethality to target cancer cells. Its revenue is currently derived from collaboration and licensing agreements with pharmaceutical firms, which is a characteristic revenue model for clinical-stage biotech developers.
TLX
Telix Pharmaceuticals
$3.94Bn
11.62
+1.48%
+17.49%
Telix is a biopharmaceutical company that develops and commercializes therapies and diagnostics derived from biological science, specifically antibody-based radiopharmaceuticals like Illuccix and Gozellix. Its core business involves the research and commercialization of biologic-based drug discovery for precision oncology.
CELC
Celcuity
$3.90Bn
79.64
+0.15%
+52.95%
Celcuity is a clinical-stage biotechnology company developing gedatolisib, a targeted therapy for solid tumors. Its revenue model currently relies on collaboration payments and milestones from partners like Pfizer, which is characteristic of biology-based drug discovery and development.
RLAY
Relay Therapeutics
$3.87Bn
17.69
+1.26%
+240.85%
Relay Therapeutics is a clinical-stage biotechnology company that uses its Dynamo platform to develop small molecule therapies for cancer and genetic diseases. Its revenue is currently derived from collaboration and milestone payments from partners like Genentech and Pfizer, which is characteristic of the H-02 classification.
VKTX
Viking Therapeutics
$3.85Bn
33.03
-7.11%
+27.97%
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically dual agonists like VK2735 (GLP-1 and GIP receptors) and thyroid hormone receptor beta agonists like VK2809. Its revenue model currently consists of collaboration agreements, licensing arrangements, and research funding typical of biotechnology developers.
DNTH
Dianthus Therapeutics
$3.76Bn
87.83
-0.81%
+122.07%
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like claseprubart and fusion proteins like DNTH212. Its revenue model consists of upfront payments, milestone payments, and royalties from collaboration agreements with partners such as Tenacia Biotechnology and Nanjing Leads Biolabs.
IDYA
IDEAYA Biosciences
$3.68Bn
38.22
+4.17%
+40.57%
IDEAYA Biosciences is a precision medicine oncology company that researches and develops therapies derived from biological science, including antibody-drug conjugates (ADCs) like IDE849 and IDE034. Its revenue model consists of upfront payments, milestone payments, and royalties from collaborations with partners such as Servier and Novartis, which is characteristic of biotechnology developers.
RADX
Radiopharm Theranostics
$3.59Bn
1.52
-7.88%
-73.79%
Radiopharm Theranostics develops therapies derived from biological science, specifically using monoclonal antibodies, nanobodies, and peptides (e.g., Nano-mAbs and PSA-mAb segments). Its revenue model consists of collaboration payments, milestones, and royalties, which is characteristic of biotechnology developers.
XENE
Xenon Pharmaceuticals
$3.55Bn
36.72
-0.60%
-5.99%
Xenon Pharmaceuticals is a biopharmaceutical company focused on drug discovery and development of therapies for neurological and psychiatric disorders. Its revenue is currently generated through collaboration agreements, milestone payments, and potential royalties, specifically citing a license and collaboration agreement with Neurocrine Biosciences.
ARQT
Arcutis Biotherapeutics
$3.43Bn
27.33
+1.52%
+46.78%
Arcutis is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting immune-mediated dermatological conditions. Its revenue is generated from the sales of ZORYVE products and collaboration/milestone payments from partners like Huadong and Sato.
DNLI
Denali Therapeutics
$3.35Bn
20.98
+2.89%
+44.49%
Denali Therapeutics is a biotechnology company developing therapies derived from biological science, specifically using its TransportVehicle platform to deliver antibodies, enzymes, and oligonucleotides. Its current revenue is derived from collaboration and milestone payments from partners like Biogen, Takeda, and Sanofi.
AMLX
Amylyx Pharmaceuticals
$3.32Bn
29.85
+1.22%
+100.34%
Amylyx is a clinical-stage company developing therapies derived from biological science, specifically antisense oligonucleotides like AMX0114 and GLP-1 receptor antagonists like avexitide. Its revenue model currently relies on collaborations and grants to fund the development of these biologic-based drug candidates.
RCUS
Arcus Biosciences
$3.18Bn
25.03
+0.40%
+87.91%
Arcus Biosciences is a biopharmaceutical company developing therapies derived from biological science, specifically antibody therapies like domvanalimab and zimberelimab. Its revenue model currently relies on collaboration and licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
ZLAB
Zai Lab
$2.88Bn
25.69
+2.84%
-21.99%
Zai Lab is a biopharmaceutical company that commercializes therapies derived from biological science, including antibody-drug conjugates like Zoci (ZL-1310) and biologics such as VYVGART and VYVGART Hytrulo. Its revenue is derived from the sales of these innovative biologic products and its pipeline focuses on biology-based drug discovery.
MBX
MBX Biosciences
$2.76Bn
57.54
+7.29%
+220.74%
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapies, such as the GLP 1/GIP co agonist MBX 4291 and the parathyroid hormone prodrug canvuparatide. These are biological science-derived therapies (peptides) developed using its proprietary PEP platform.
TAK
2nd
Takeda Pharmaceutical
$2.74Bn
18.91
+0.27%
+29.34%
The company operates as a biopharmaceutical firm and commercializes therapies derived from biological science, specifically within its Plasma-Derived Therapies segment which produces immunoglobulin and albumin products like GAMMAGARD LIQUID.
DYN
Dyne Therapeutics
$2.71Bn
16.34
+1.93%
+32.09%
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically using its FORCE platform to deliver oligonucleotides and enzymes. Its lead candidates, z-rostudirsen and z-basivarsen, are biologics targeting neuromuscular diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.
SUPN
2nd
Supernus Pharmaceuticals
$2.59Bn
44.60
+4.55%
-6.30%
The company describes itself as a biopharmaceutical company and utilizes proprietary formulation technologies to develop novel product candidates for neuropsychiatric conditions, including the acquisition of Sage Therapeutics to expand its biologic-based therapy footprint.
IRON
Disc Medicine
$2.49Bn
64.92
-0.49%
-0.22%
Disc Medicine is a clinical-stage biopharmaceutical company developing therapies derived from biological science to treat hematologic diseases. Its revenue model currently relies on licensing agreements and milestone payments for candidates like bitopertin, DISC 0974, and DISC 0998.
CLDX
Celldex Therapeutics
$2.47Bn
31.49
+1.25%
+20.24%
Celldex Therapeutics is a biopharmaceutical company focused on developing therapies derived from biological science, specifically monoclonal and bispecific antibodies like barzolvolimab and CDX-622. Its revenue model currently consists of partnership agreements, licensing arrangements, and milestone payments from collaborators, which is characteristic of clinical-stage biotechnology developers.
HCM
HUTCHMED (China)
$2.47Bn
14.13
+1.36%
-9.77%
HUTCHMED is a biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies, such as savolitinib and fruquintinib. Its revenue is derived from the sale of these biologic-focused oncology drugs and milestone payments from partners like AstraZeneca and Eli Lilly.
IMNM
Immunome
$2.46Bn
21.68
+1.26%
+91.18%
Immunome is a clinical-stage biotechnology company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like IM-1021 and radioligand therapies like IM-3050. Its revenue model is based on strategic partnerships, licensing agreements, and milestone payments typical of biotech developers.
NRIX
Nurix Therapeutics
$2.45Bn
23.67
+2.87%
+155.06%
Nurix Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation medicines. Its revenue is derived from collaboration and milestone payments from partners like Gilead, Sanofi, and Pfizer, and it focuses on biology-based drug discovery using its DEL-AI platform.
VERA
Vera Therapeutics
$2.34Bn
32.50
-0.12%
+12.46%
Vera Therapeutics is a biotechnology company developing therapies derived from biological science, specifically atacicept, which is a human TACI Fc fusion protein. The company also develops MAU868, a monoclonal antibody, both of which are biologic-based drug candidates.
SLS
SELLAS Life Sciences
$2.34Bn
11.59
-0.17%
+642.95%
SELLAS is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically galinpepimut S, a peptide immunotherapy. Its revenue is currently generated through milestone and royalty payments from collaboration agreements, such as the one with 3D Medicines.
VRDN
Viridian Therapeutics, Inc.\DE
$2.33Bn
20.57
+0.49%
-4.81%
Viridian Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like veligrotug and elegrobart. Its product pipeline focuses on biology-based drug discovery for thyroid eye disease and autoimmune disorders.
AXGN
2nd
Axogen
$2.33Bn
43.36
-0.07%
+151.22%
The company develops and commercializes the Avance Nerve Graft, which is a biologically active nerve allograft. This biologic product is approved under the FDA's Section 351 pathway for bridging peripheral nerve discontinuities.
HRMY
2nd
Harmony Biosciences Holdings
$2.33Bn
40.01
-3.03%
+44.75%
The company maintains a significant biotechnology pipeline, including the development of synthetic cannabidiol gels (ZYN002) and other biological-based research for rare epilepsy and neurobehavioral conditions.
ADMA
Adma Biologics
$2.28Bn
10.12
+7.89%
-31.16%
Adma Biologics is a biopharmaceutical company that develops and manufactures biologics derived from human plasma, specifically immune globulin products like ASCENIV, BIVIGAM, and Nabi HB. Its core revenue is derived from the sale of these biologic therapies used to treat immunodeficient patients.
GMAB
Genmab A
$2.27Bn
35.36
+0.11%
+20.56%
Genmab is a biotechnology company that develops and commercializes antibody-based therapies, such as epcotamab and tisotumab vedotin. Its revenue is derived from biologic product sales, royalties from partnered biologics like daratumumab and rybrevant, and milestone payments from collaborations with partners like AbbVie and BioNTech.
AUPH
2nd
Aurinia Pharmaceuticals
$2.20Bn
16.52
+0.49%
+49.37%
The company maintains a research and development pipeline focused on aritinercept, a dual inhibitor of BAFF and APRIL designed to treat autoimmune diseases. This activity involves the development of biological therapies derived from biological science, which is characteristic of biotechnology.
BCRX
Biocryst Pharmaceuticals
$2.16Bn
8.47
-1.40%
+12.19%
BioCryst is a biotechnology company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Navenibart and STAR-0310, and protein therapeutics like BCX17725. Its revenue model includes biologic product sales, licensing agreements, and milestone payments from collaborators such as Torii Pharmaceutical and Shionogi.
XTLB
Xtl Biopharmaceuticals
$2.11Bn
2.23
-0.89%
-53.93%
The company develops and commercializes biopharmaceutical intellectual property, specifically the hCDR1 synthetic peptide for treating systemic lupus erythematosus and Sjogren’s syndrome. It generates revenue through a sublicense agreement with Biossil Inc., including potential milestone payments.
PHVS
Pharvaris
$2.08Bn
31.91
-0.34%
+31.53%
Pharvaris is a biopharmaceutical company developing deucrictibant, a novel oral therapy targeting the bradykinin B2 receptor for rare diseases. Its business model is centered on the research, development, and planned commercialization of these biological-science-based therapies.
BHVN
Biohaven
$2.00Bn
13.27
+2.23%
-9.48%
Biohaven is a clinical-stage biopharmaceutical company developing therapies derived from biological science, including antibody-drug conjugates (ADCs) like BHV-1510 and BHV-1530 in its oncology segment. Its business model focuses on biology-based drug discovery and development across immunology, neuroscience, and oncology.
URGN
UroGen Pharma
$2.00Bn
40.90
-1.09%
+113.69%
UroGen Pharma is described as a biotechnology company that develops therapies derived from biological science, specifically utilizing its proprietary RTGel reverse thermal hydrogel platform. Its revenue is generated from the sale of biologic-based products like Jelmyto and Zusduri, as well as potential milestone payments and royalties from licensing agreements.
NKTR
Nektar Therapeutics
$2.00Bn
60.40
+5.85%
+2.51%
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically immunomodulatory agents and biologics like NKTR-255 targeting the IL-15 pathway. Its revenue model is based on collaboration agreements, royalties, and milestone payments from partnered drug programs.
AGIO
Agios Pharmaceuticals
$1.99Bn
33.42
+2.58%
-14.90%
Agios is a biopharmaceutical company that leverages expertise in cellular metabolism to develop therapies for rare diseases, such as PYRUKYND® and AQVESME™. Its revenue is derived from the sale of these biologic-focused medicines, as well as milestone payments and royalties from licensing arrangements like the AG 236 siRNA program.
SRPT
2nd
Sarepta Therapeutics
$1.99Bn
18.80
+0.70%
-0.11%
The company develops and sells RNA-targeted therapeutics and siRNA knockdown therapies, such as EXONDYS 51, VYONDYS 53, and AMONDYS 45, which are biologic-based medicines.
RXRX
Recursion Pharmaceuticals
$1.98Bn
3.70
-1.07%
-24.64%
Recursion is a clinical-stage biotechnology company that researches and develops therapies using a proprietary drug discovery platform. Its revenue is derived from collaboration and milestone payments from pharmaceutical partners like Roche, Genentech, and Sanofi.
LKFT
Lakefront Biotherapeutics
$1.97Bn
29.84
+1.57%
-13.33%
Galapagos NV is a biotechnology company that researches and develops therapies for immunology and oncology, generating revenue from collaboration payments and royalties. Its business model focuses on biology-based drug discovery and development, as evidenced by its pipeline of therapeutic programs.
NUVB
2nd
Nuvation Bio
$1.94Bn
5.61
-1.92%
+74.22%
The company operates a drug-drug conjugate technological framework and develops therapies like safusidenib, utilizing biotechnology-based research and development for its oncology pipeline.
ZYME
Zymeworks
$1.94Bn
27.12
+2.26%
+57.40%
Zymeworks is a biotechnology company that develops therapies derived from biological science, specifically multispecific antibodies and antibody-drug conjugates like ZW191 and ZW220. Its revenue is derived from biologic product collaborations, milestone payments, and royalties from partners such as Jazz Pharmaceuticals and BeOne.
SDGR
2nd
Schrodinger
$1.94Bn
29.50
+2.25%
+47.21%
The company operates a Drug Discovery segment where it develops a proprietary pipeline of therapeutic candidates and conducts collaborative research with biopharma partners, earning revenue from milestones and royalties.
XNCR
Xencor
$1.90Bn
25.60
+7.56%
+121.65%
Xencor is a clinical-stage biopharmaceutical company that develops engineered antibody therapeutics, specifically using its XmAb platform to create bispecific antibodies and recombinant proteins. Its revenue is derived from biologic product collaborations, milestone payments, and royalties from marketed medicines like Monjuvi and Ultomiris.
SEPN
Septerna
$1.81Bn
39.74
+5.22%
+118.95%
Septerna is a clinical-stage biotechnology company that uses its proprietary Native Complex Platform to research and develop therapies derived from biological science, specifically targeting G protein coupled receptors. Its revenue is generated through collaboration agreements, upfront payments, and potential milestones with pharmaceutical partners like Novo Nordisk.
CMPS
COMPASS Pathways
$1.80Bn
13.23
+1.30%
+125.38%
Compass Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary formulation of psilocybin for treatment-resistant depression and PTSD. Its business model focuses on biology-based drug discovery and development, currently financing operations through equity and collaboration agreements while conducting Phase 2b and Phase 3 clinical trials.
NVAX
Novavax
$1.78Bn
10.80
+1.60%
+26.02%
Novavax is a biotechnology company that develops therapies derived from biological science, specifically using a recombinant nanoparticle vaccine technology and a baculovirus insect cell expression system. Its revenue is generated from the sale of its COVID-19 vaccine (Nuvaxovid) and milestone payments from collaborations with partners like Sanofi and Pfizer.
VIR
Vir Biotechnology
$1.78Bn
10.51
-1.41%
+86.68%
Vir Biotechnology is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody combinations and T cell engagers. Its revenue is currently generated through collaboration and licensing agreements, milestone payments, and royalties, which is characteristic of the Biotechnology industry.
ATAI
Atai Beckley
$1.77Bn
7.35
+0.00%
+59.78%
Atai is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically psychedelic-based therapies and novel compounds like dimethyltryptamine and psilocin. Its revenue model is based on the typical biotechnology pattern of collaboration, milestone payments, and future royalties/sales of biologic-based drug candidates.
ZBIO
Zenas BioPharma
$1.74Bn
27.55
+2.23%
+33.93%
Zenas BioPharma is a clinical-stage biopharmaceutical company focusing on therapies derived from biological science, specifically monoclonal antibodies like obexelimab. Its revenue model currently consists of upfront licensing payments, milestone payments, and royalties from partners such as Bristol Myers Squibb and InnoCare.
OCUL
Ocular Therapeutix
$1.68Bn
7.66
-20.62%
-38.87%
Ocular Therapeutix is a biopharmaceutical company utilizing its proprietary ELUTYX hydrogel technology platform to develop therapies. Its revenue is derived from the sale of DEXTENZA, a corticosteroid insert, and milestone payments from collaborations for biologic-based delivery systems.
ABSI
Absci
$1.63Bn
9.49
-2.57%
+219.53%
Absci is a clinical-stage biopharmaceutical company that researches and develops antibody-based therapeutics, such as ABS-201, using biological science. Its revenue model includes the development of its own pipeline and receiving milestone payments and royalties from biologic product collaborations.
RAPP
Rapport Therapeutics
$1.60Bn
33.44
-1.39%
+19.56%
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines, such as its lead candidate RAP 219, for neurological and psychiatric disorders. Its business model relies on its RAP technology platform for biology-based drug discovery and development.
SNDX
Syndax Pharmaceuticals
$1.59Bn
17.86
-1.87%
+14.78%
Syndax is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Niktimvo (axatilimab). Its revenue is generated from the sales of these biologic products, as well as collaboration milestones and royalties.
STOK
Stoke Therapeutics
$1.59Bn
25.50
+2.82%
+3.11%
Stoke Therapeutics develops RNA-based medicines, specifically antisense oligonucleotides (ASOs), which are categorized as oligonucleotide medicines under Biotechnology. The company's revenue is derived from collaboration and milestone payments from partners like Acadia Pharmaceuticals and Biogen, typical for clinical-stage biotech developers.
NBTX
Nanobiotix
$1.58Bn
32.60
-2.13%
+80.91%
Nanobiotix is a clinical-stage biotechnology company developing nanotherapeutics, such as the hafnium oxide-based nanoparticle JNJ-1900 (NBTXR3). Its revenue model is based on biotechnology-typical sources, including strategic collaborations, licensing agreements, and milestone payments from partners like Janssen Pharmaceutica NV.
IMCR
Immunocore Holdings
$1.58Bn
30.64
-0.26%
-10.77%
Immunocore is a biotechnology company that develops therapies derived from biological science, specifically using its ImmTAX platform to engineer T-cell receptors. It generates revenue from the sale of KIMMTRAK (tebentafusp), a biologic product used to treat uveal melanoma.
FBRX
Forte Biosciences
$1.58Bn
76.99
+0.00%
—
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, which is a monoclonal antibody. Its core business is the research and development of therapies derived from biological science to treat autoimmune diseases.
INBX
Inhibrx Biosciences
$1.50Bn
101.71
+2.11%
+214.79%
Inhibrx is a clinical-stage biopharmaceutical company developing biologic therapeutics, specifically multi-specific biologics and agonists like ozekibart and INBRX 106. Its revenue model is based on potential milestone and royalty payments from collaborations, which is characteristic of biotechnology developers.
MAZE
Maze Therapeutics
$1.49Bn
26.85
+3.07%
+6.55%
Maze Therapeutics is a clinical-stage biopharmaceutical company that uses its proprietary Compass platform for biology-based drug discovery and development. It develops therapies derived from human genetics and functional genomics, such as the APOL1 inhibitor MZE829 and the SLC6A19 inhibitor MZE782, and generates revenue through milestone payments and royalties from biotechnology partners.
ANAB
Anaptysbio
$1.47Bn
50.80
-0.39%
+227.53%
Anaptysbio is a clinical-stage biotechnology company developing antibody-based therapeutics such as rosnilimab, ANB033, and ANB101. Its revenue is derived from biologic-related sources including milestone payments and royalties from collaborations with GSK and Vanda.
GHRS
GH Research
$1.45Bn
23.42
-1.76%
+61.18%
GH Research is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies, such as GH001 and GH002, for psychiatric and neurological disorders. Its business model focuses on biology-based drug discovery and development for treatment-resistant depression.
RARE
Ultragenyx Pharmaceutical
$1.42Bn
14.41
-0.62%
-52.54%
Ultragenyx is a biopharmaceutical company that develops and commercializes therapies derived from biological science, including biologics and enzyme replacement therapies like Mepsevii. Its revenue is generated from the sale of these biologic products and through collaboration agreements and milestone payments with partners such as Kyowa Kirin and Regeneron.
AVBP
ArriVent BioPharma
$1.42Bn
29.30
+2.99%
+61.34%
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like ARR 217 and ARR 002. Its revenue model currently consists of collaboration and milestone payments, which is characteristic of biotechnology developers.
AAPG
Ascentage Pharma Group International
$1.41Bn
15.08
+1.75%
-60.88%
Ascentage Pharma is a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically targeting apoptotic pathways and tyrosine kinase signaling. Its lead assets, Olverembatinib and Lisaftoclax, are developed using a proprietary drug discovery platform focused on biological targets in hematological malignancies.
OMER
Omeros
$1.40Bn
19.43
-3.24%
+364.83%
Omeros is a biotechnology company that develops therapies derived from biological science, specifically protein therapeutics and antibodies such as YARTEMLEA (narsoplimab-wuug) and OMS1029. Its revenue is generated from the sale of these biologic products and collaboration payments from partners like Novo Nordisk.
ORIC
Oric Pharmaceuticals
$1.38Bn
13.27
+0.84%
+14.20%
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting PRC2 dysregulation and EGFR exon 20 mutations. Its revenue is currently derived from upfront payments, milestone payments, and royalties from licensing and collaboration agreements, which is characteristic of the Biotechnology industry.
SCNI
Scinai Immunotherapeutics
$1.37Bn
1.47
-5.16%
-87.75%
Scinai Immunotherapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies and NanoAbs for inflammatory diseases like psoriasis and pemphigus. Its R&D segment focuses on the discovery and development of these biologic-based drug candidates.
DMRA
Damora Therapeutics
$1.28Bn
20.75
+0.44%
+446.05%
Damora Therapeutics is a biopharmaceutical company developing monoclonal antibodies, specifically DMR-001, DMR-002, and DMR-003, to treat hematologic disorders. These are therapies derived from biological science targeting the mutant calreticulin protein (mutCALR), which fits the definition of biotechnology.
TYRA
Tyra Biosciences
$1.28Bn
21.45
-1.42%
+61.28%
Tyra Biosciences is a clinical-stage biotechnology company that uses its proprietary SNÅP platform to research and develop therapies derived from biological science, specifically small molecule inhibitors targeting FGFR signaling. Its pipeline includes candidates like dabogratinib for urothelial carcinoma and achondroplasia, and TYRA-430 for hepatocellular carcinoma.
BCAX
Bicara Therapeutics
$1.24Bn
18.80
-2.13%
+35.54%
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies, specifically ficerafusp alfa, which is a biologic derived from biological science. Its core business is the research and development of these monoclonal antibody-based therapies for solid tumors.
IMTX
2nd
Immatics
$1.14Bn
8.50
+1.55%
+7.46%
The company develops 'off the shelf bispecific molecules' (TCER segment) produced via mammalian cell expression systems, which are biologic products typical of the biotechnology industry.
REPL
Replimune
$1.05Bn
12.56
+1.62%
+189.40%
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies derived from an engineered strain of herpes simplex virus 1 (HSV-1). Its product candidates, such as RP1 and RP2, are biologics designed to selectively replicate in tumors and stimulate immune responses.
SVRA
Savara
$1.04Bn
5.07
+1.40%
+44.03%
Savara is a clinical-stage biopharmaceutical company developing molgramostim inhalation solution (MOLBREEVI), which is described as an inhaled biologic delivering recombinant human granulocyte macrophage colony stimulating factor. This fits the H-02 classification for companies researching and developing therapies derived from biological science, such as recombinant proteins.
MNKD
Mannkind
$1.04Bn
3.35
+0.30%
-37.85%
MannKind is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically inhaled insulin (Afrezza) and inhaled treprostinil (Tyvaso DPI). Its revenue is driven by the sale of these biologic products and royalties from collaborations with partners like United Therapeutics.
JANX
Janux Therapeutics
$1.01Bn
16.58
+1.72%
-30.04%
Janux Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically T cell engagers and immunomodulators using its TRACTr, TRACIr, and ARM platforms. Its revenue is currently derived from collaboration and milestone payments from partners like Merck and Bristol Myers Squibb, which is characteristic of biotechnology developers.
CRVS
Corvus Pharmaceuticals
$998.52Mn
11.87
+2.15%
+63.05%
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like mupadolimab. Its revenue model currently relies on collaboration, milestone payments, and royalties, which is characteristic of biotechnology developers.
GLUE
Monte Rosa Therapeutics
$998.00Mn
11.71
-0.51%
+60.19%
Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically molecular glue degraders. Its revenue is currently derived from collaboration and milestone payments from partners like Novartis and Roche, which is characteristic of the H-02 classification.
VOR
Vor Biopharma
$997.08Mn
18.31
-1.13%
-54.10%
Vor Biopharma is a clinical-stage biopharmaceutical company developing telitacicept, which is described as a recombinant fusion protein. This biology-based drug discovery and development for autoimmune diseases fits the Biotechnology classification.
MLTX
MoonLake Immunotherapeutics
$983.83Mn
11.56
-3.99%
+85.26%
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing Nanobody-based treatments, which are biological therapies. Its primary asset, SLK, is a tri-specific Nanobody designed to inhibit IL-17A and IL-17F cytokines for inflammatory diseases.
CGEM
Cullinan Therapeutics
$961.97Mn
14.95
+0.95%
+150.42%
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically T cell engagers and bispecific antibodies like CLN-978 and CLN-049. Its revenue model is based on collaboration agreements, milestone payments, and royalties from partners such as Taiho Pharmaceutical.
ABUS
Arbutus Biopharma
$960.50Mn
4.86
+0.21%
+8.97%
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically imdusiran, a GalNAc conjugated RNAi therapeutic. Its revenue model consists of licensing agreements, milestone payments, and royalties from biologic products like Alnylam's ONPATTRO.
ANRO
Alto Neuroscience
$935.96Mn
26.67
+0.72%
+565.09%
Alto Neuroscience is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders such as major depressive disorder and schizophrenia. Its revenue model currently consists of upfront fees, milestone payments, and royalties from collaborations with partners like Sanofi and Cerecor, which is characteristic of biotechnology developers.
RIGL
Rigel Pharmaceuticals
$922.04Mn
49.36
+2.45%
+71.69%
Rigel is described as a biotechnology company that develops therapies derived from biological science, specifically targeting signaling pathways for hematologic disorders and cancer. Its revenue is derived from the sale of biologic-based products like TAVALISSE, REZLIDHIA, and GAVRETO, as well as collaboration and milestone payments.
OKYO
OKYO Pharma
$921.69Mn
1.37
-0.72%
-31.50%
OKYO Pharma is a clinical-stage biopharmaceutical company developing urcosimod, which is described as a lipidated peptide. This falls under the biotechnology category as it involves therapies derived from biological science (peptides) and the company's revenue model relies on milestone payments and potential biologic product sales.
JBIO
Jade Biosciences
$912.03Mn
14.35
-0.49%
+66.47%
Jade Biosciences is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies, such as JADE101 and JADE201, which are biologics. Its business model focuses on the research and development of these biological therapies for autoimmune diseases.
CLYM
Climb Bio
$894.05Mn
11.74
+0.69%
+489.95%
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibodies, specifically budoprutug (anti-CD19) and CLYM116 (anti-APRIL). Its revenue is derived from collaboration agreements, milestone payments, and royalties, which is characteristic of the H-02 Biotechnology industry.
ALMS
Alumis
$891.03Mn
7.16
+0.85%
+81.27%
Alumis is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like lonigutamab and targeted inhibitors for immune-mediated diseases. Its business model focuses on biology-based drug discovery and development using a precision data analytics platform integrating genomic and proteomic information.
TBPH
Theravance Biopharma
$883.70Mn
17.03
+0.00%
+23.50%
Theravance Biopharma is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting respiratory diseases. Its revenue is driven by biologic-related product sales, profit-sharing agreements for YUPELRI, and milestone payments from partnerships with GSK and Viatris.
ARDX
Ardelyx
$849.59Mn
3.41
-0.29%
-39.43%
Ardelyx is a biopharmaceutical company that researches, develops, and commercializes therapies derived from biological science, specifically its lead asset tenapanor. The company generates revenue from the sales of biologic-based products like IBSRELA and XPHOZAH, as well as milestone payments and royalties from collaboration partners such as Kyowa Kirin and Fosun Pharma.
STTK
Shattuck Labs
$834.48Mn
6.43
+5.93%
+183.26%
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies, such as SL-325 and SL-425, which are biologic therapies. Its revenue model is typical for biotech, relying on equity financing and potential collaboration payments and royalties.
GERN
Geron
$803.09Mn
1.25
-0.79%
-4.58%
Geron is a biopharmaceutical company that developed RYTELO (imetelstat), a first-in-class telomerase inhibitor derived from biological science to treat myelodysplastic syndromes. The company generates revenue from the sale of this biologic product to healthcare providers and hospitals.
ACRS
Aclaris Therapeutics
$759.25Mn
5.43
+5.44%
+182.81%
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies and bispecific antibodies like bosakitug and ATI-052. Its revenue model consists of upfront licensing fees, milestone payments, and royalties from collaborations with partners such as Biosion.
PHAR
Pharming
$738.17Mn
10.52
+0.57%
-25.81%
Pharming is a biotechnology company that develops and commercializes therapies derived from biological science, specifically RUCONEST®, which is a recombinant C1 esterase inhibitor protein replacement therapy. Its revenue is generated from the sale of these biologic products for rare and ultra-rare diseases.
MNPR
Monopar Therapeutics
$715.17Mn
83.72
-1.78%
+10.30%
Monopar is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically MNPR 101, which is a humanized monoclonal antibody used for oncology imaging and therapy. The company's revenue model includes licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
WVE
Wave Life Sciences
$709.33Mn
3.67
-2.91%
-48.53%
Wave Life Sciences is a clinical-stage biotechnology company developing therapies derived from biological science, specifically RNA-based medicines including siRNA and antisense oligonucleotides. Its revenue is currently generated through collaboration agreements, milestone payments, and royalties from partners like GSK and Takeda.
VSTM
2nd
Verastem
$703.05Mn
7.77
+0.39%
-10.07%
The company maintains a pipeline of biology-based drug discovery, including VS-7375, an oral small-molecule inhibitor for KRAS G12D mutations currently in Phase 1/2 trials. It also receives milestone payments and royalties from collaborations with other biotech and pharma firms like GenFleet.
ANNX
Annexon
$700.16Mn
4.01
+10.16%
+28.53%
Annexon is a biopharmaceutical company developing targeted immunotherapies, specifically complement protein C1q inhibitors, which are biological therapies. The company is a clinical-stage developer with no current product revenue, focusing on biological science to treat neuroinflammatory diseases.
OABI
OmniAb
$689.15Mn
4.74
+2.82%
+194.41%
OmniAb's core business is a biotechnology platform that uses engineered transgenic animals and biological intelligence to discover and optimize antibodies and other target-binding proteins for human therapeutics. Its revenue is primarily derived from license agreements, milestones, and royalties from pharmaceutical and biotech partners developing biologic products.
IRWD
Ironwood Pharmaceuticals
$680.79Mn
4.12
-0.24%
+190.14%
Ironwood Pharmaceuticals is described as a biotechnology company that develops therapies derived from biological science, specifically mentioning apraglutide, which is a peptide analog. Its revenue model includes biologic product sales, royalties, and milestone payments from partners like AstraZeneca and Astellas.
ZVRA
2nd
Zevra Therapeutics
$670.56Mn
11.30
+2.36%
+18.45%
The company utilizes a proprietary Ligand Activated Technology platform and develops clinical-stage assets like celiprolol and KP1077, which are characteristic of biotechnology-driven drug discovery and development.
AVTX
Avalo Therapeutics
$657.52Mn
15.08
-2.52%
+15.82%
Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), which is described as a humanized IgG monoclonal antibody. Its business model focuses on the research and development of biologics to treat immune-mediated inflammatory diseases.
AURA
Aura Biosciences
$636.40Mn
6.15
+2.50%
-0.32%
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a virus-like drug conjugate (VDC) derived from biological science for targeted cancer therapy. Its revenue model is based on the development of these biologic candidates and potential future milestone payments or royalties.
FLGT
2nd
Fulgent Genetics
$615.24Mn
22.36
+0.72%
+0.27%
The company has a therapeutic development division focused on creating new drug formulations using nanoencapsulation technology, with candidates like FID 007 and FID 022 currently in phase one and two clinical trials.
CRMD
2nd
CorMedix
$612.79Mn
7.89
+0.51%
-33.42%
The company describes itself as a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases, which aligns with the research and commercialization of biology-based therapies.
CYPH
2nd
Cypherpunk Technologies
$610.13Mn
3.31
-19.66%
+819.44%
Through its subsidiary Leap Therapeutics, the company develops antibody therapies for cancer, specifically leveraging a proprietary anti-DKK1 antibody platform for oncology treatments.
IBO
Impact Biomedical
$607.03Mn
5.63
+0.18%
+753.03%
Impact Biomedical focuses on the discovery and patenting of biopharmaceuticals and drug discovery for neurological, oncologic, and inflammatory conditions. Its revenue model is based on licensing these biological technologies to partners like ProPhase Laboratories in exchange for upfront fees, milestones, and royalties.
CTMX
CytomX Therapeutics
$586.15Mn
2.69
-0.37%
-16.72%
CytomX is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically masked biologics including antibody-drug conjugates (ADCs), T-cell engagers, and cytokines. Its revenue is generated through collaboration and milestone payments from partners like Amgen and Bristol Myers Squibb, which is characteristic of the Biotechnology industry.
CNTN
2nd
Canton Strategic Holdings
$583.37Mn
2.69
+4.67%
-7.24%
The company maintains a Biotechnology Research and Development segment through its subsidiary Gravitas, focusing on biologic therapeutic candidates like GV104 and GV023 for immunology and inflammation.
ALT
Altimmune
$575.64Mn
2.96
-3.27%
-21.90%
Altimmune is a biopharmaceutical company developing pemvidutide, a peptide engineered as a dual agonist of glucagon and GLP1 receptors. Its revenue model is typical of clinical-stage biotechnology firms, deriving from licensing arrangements and collaborative agreements while developing biologic-based therapies.
VALN
Valneva SE
$561.40Mn
6.47
+5.37%
-40.91%
Valneva SE is a specialty vaccine company that develops and commercializes biologic therapies, specifically prophylactic vaccines like IXIARO, DUKORAL, and IXCHIQ. Its business model relies on the sale of these biologic products and the development of a clinical pipeline including candidates for Lyme disease and Zika virus.
SLN
Silence Therapeutics
$529.16Mn
11.20
+0.18%
+97.53%
Silence Therapeutics is a biotechnology company that develops therapies derived from biological science, specifically using siRNA and its proprietary mRNAi GOLD™ platform to target messenger RNA. Its revenue is currently derived from collaboration and milestone payments from pharmaceutical partners like AstraZeneca and Hansoh for its RNAi-based drug candidates.
ANL
Adlai Nortye
$528.79Mn
15.40
-0.84%
+770.06%
Adlai Nortye is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody-drug conjugates (AN4035) and tri-specific antibody fusion proteins (AN8025). Its revenue is currently derived from collaboration and milestone payments from partners like Eisai and ASK Pharm, which is characteristic of biotechnology developers.
SGMT
Sagimet Biosciences
$527.96Mn
9.94
+7.58%
+43.64%
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing FASN inhibitors, such as denifanstat and TVB-3567, which are therapies derived from biological science. Its revenue model consists of licensing agreements and milestone payments from collaborators like Ascletis BioScience Co. Ltd.
ZURA
Zura Bio
$519.90Mn
4.10
+1.49%
+37.12%
Zura Bio is a clinical-stage biotechnology company developing antibody-based therapies, such as tibulizumab and torudokimab, derived from biological science. Its revenue model relies on equity offerings, debt, and potential milestone payments from partnerships with larger pharmaceutical firms.
YDES
YD Bio
$503.31Mn
7.11
+24.08%
-60.65%
YD Bio is a biopharmaceutical company developing therapies derived from biological science, specifically mesenchymal stem cells and exosomes for ocular conditions like dry eye disease and glaucoma. Its revenue model includes the future sale of exosome-based eye drops and contact lenses.
PBYI
Puma Biotechnology
$501.83Mn
9.82
+0.51%
+94.46%
Puma Biotechnology is a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically focusing on oncology. Its lead product, NERLYNX (neratinib), and its investigational drug alisertib are developed to treat HER2 positive breast cancer and small cell lung cancer.
KMDA
Kamada
$497.25Mn
8.62
-1.15%
+25.47%
Kamada is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically immunoglobulins extracted and purified from human plasma. Its proprietary products include KEDRAB, GLASSIA, and CYTOGAM, and it generates significant revenue from these biologic sales and royalties from Takeda.
ARVN
Arvinas
$490.40Mn
7.51
-1.05%
-11.96%
Arvinas is a clinical-stage biotechnology company that develops therapies using its proprietary PROTAC platform to degrade disease-causing proteins. Its revenue is derived from collaboration and licensing agreements with partners like Pfizer and Novartis, including upfront payments and milestones.
CTNM
Contineum Therapeutics
$476.97Mn
12.73
+1.35%
+7.70%
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies derived from biological science, specifically modulating biological pathways like the lysophosphatidic acid 1 receptor. Its revenue is derived from collaboration agreements, licensing deals, and milestone payments, such as its agreement with Johnson & Johnson for the PIPE-307 asset.
OCS
Oculis Holding AG
$473.32Mn
9.06
-2.27%
-48.35%
Oculis Holding AG is a biopharmaceutical company developing therapies derived from biological science, specifically Licaminlimab, which is a single chain antibody fragment. The company's core business is the research and development of these biologic-based drug candidates for ophthalmic diseases.
ASMB
Assembly Biosciences
$468.67Mn
23.61
-0.25%
-4.14%
Assembly Biosciences is a biotechnology company that researches and develops antiviral therapies, such as the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334. Its revenue is derived from collaboration and licensing agreements, including upfront and milestone payments from Gilead Sciences.
NEUP
Neuphoria Therapeutics
$455.01Mn
3.65
-0.54%
-69.22%
Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, specifically its lead candidate BNC210. Its revenue is derived from collaboration and milestone payments from partners like Merck, which is characteristic of the H-02 biotechnology classification.
OVID
2nd
Ovid Therapeutics
$454.50Mn
2.46
+2.50%
+75.71%
The company has a research collaboration with Gensaic Inc to develop up to three genetic medicines for neurological indications using a tissue-selective intracellular delivery platform, which falls under biology-based drug discovery.
TECX
Tectonic Therapeutic
$452.22Mn
23.51
-0.68%
+47.68%
Tectonic Therapeutic is a clinical-stage biotechnology company developing therapies derived from biological science, specifically therapeutic proteins and antibodies such as the TX45 Fc-relaxin fusion molecule and TX2100 VHH-Fc fusion antagonist antibody. Its core business is biology-based drug discovery using its proprietary GEODe platform to target G-protein coupled receptors.
PRTA
Prothena Corp Public
$451.21Mn
8.72
+5.19%
-10.66%
Prothena is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically targeting protein dysregulation and misfolded proteins using its CYTOPE® platform. Its revenue is derived from collaboration and milestone payments from partners like Roche, Novo Nordisk, and Bristol Myers Squibb for biologic candidates targeting Parkinson's and Alzheimer's diseases.
DMAC
DiaMedica Therapeutics
$448.66Mn
8.32
+4.79%
+20.41%
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), which is a recombinant human tissue kallikrein-1 (rhKLK1) protein. This is a biologic therapy derived from biological science, fitting the description of biotechnology-focused drug development.
AVIR
Atea Pharmaceuticals
$417.06Mn
5.20
+0.58%
+78.08%
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically a proprietary platform of nucleosides and nucleotides. Its lead candidates, bemnifosbuvir and AT 587, are nucleotide analogs being developed to treat hepatitis C and hepatitis E.
ARCT
Arcturus Therapeutics Holdings
$411.00Mn
14.46
+4.40%
-23.00%
Arcturus is a biotechnology company focused on developing therapies and vaccines derived from biological science, specifically using a proprietary self-amplifying mRNA platform. Its revenue is generated from biologic product sales of its COVID-19 vaccine KOSTAIVE, as well as collaboration and milestone payments from partners like CSL Seqirus.
IMUX
Immunic
$404.31Mn
9.51
+1.71%
+1.71%
Immunic is a biotechnology company researching and developing therapies derived from biological science, specifically targeting immunological targets for neurologic and gastrointestinal diseases. Its pipeline includes candidates like vidofludimus calcium (IMU 838) and IMU 856, which are currently in clinical stages.
RLMD
Relmada Therapeutics
$404.28Mn
3.79
-1.04%
+101.60%
Relmada Therapeutics is a clinical-stage biotechnology company developing therapies such as sepranolone, a neurosteroid epimer, and NDV-01. The company's business model is based on biology-based drug discovery and development, with anticipated future revenue from product sales, milestones, and royalties.
CBIO
Crescent Biopharma
$403.30Mn
14.53
+3.86%
+18.23%
Crescent Biopharma is a clinical-stage biotechnology company developing therapies derived from biological science, specifically bispecific antibodies and antibody drug conjugates. Its revenue is currently derived from upfront payments, milestone payments, and royalties from collaboration and licensing agreements with partners.
RZLT
Rezolute
$402.98Mn
4.18
+7.18%
-55.01%
Rezolute is a biotechnology company developing ersodetug, which is described as a human monoclonal antibody. The company's core business is the research and development of this biologic therapy for rare diseases like congenital and tumor-associated hyperinsulinism.
AGEN
Agenus
$401.87Mn
9.43
+10.42%
+136.93%
Agenus is a clinical-stage biotechnology company developing immune-modulatory antibodies and therapies derived from biological science to fight cancer and infections. Its revenue is derived from biologic-related royalty streams, upfront licensing payments, and milestones from partners like Bristol-Myers Squibb and Merck.
OFIX
2nd
Orthofix Medical
$400.78Mn
9.84
+4.24%
-31.48%
The company sells biologics, including demineralized bone matrices, cellular allografts, and synthetic bone graft substitutes, which are therapies derived from biological science used to enhance bone fusion.
DRUG
Bright Minds Biosciences
$394.46Mn
51.66
-0.27%
-10.08%
Bright Minds Biosciences is a biotechnology company developing therapies derived from biological science, specifically targeting serotonin receptor subtypes for neurological and psychiatric disorders. Its lead candidate BMB 101 and other pipeline compounds (BMB 105, BMB 201, BMB 202) are developed using a proprietary platform of biased agonists and structure-based drug design.
CCCC
C4 Therapeutics
$383.47Mn
3.12
+4.70%
+39.91%
C4 Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation using its TORPEDO platform. Its revenue is currently derived from collaboration and milestone payments from partners like Pfizer, Merck KGaA, and Roche, which is characteristic of biotechnology developers.
ENTA
Enanta Pharmaceuticals
$367.20Mn
12.61
+6.14%
-16.82%
Enanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule therapeutics for virology and immunology, specifically targeting RSV, SARS-CoV-2, and hepatitis B. Its revenue model includes royalty payments from its collaboration with AbbVie for the hepatitis C regimen MAVYRET/MAVIRET, as well as potential milestone payments from its proprietary pipeline.
OCGN
2nd
Ocugen
$349.22Mn
1.03
+0.98%
-28.97%
The company develops a regenerative medicine cell therapy platform featuring NeoCart, an autologous chondrocyte-derived neocartilage implant for knee cartilage repair, which falls under the commercialization of therapies derived from biological science.
SRZN
Surrozen
$348.39Mn
29.64
+0.34%
+154.20%
Surrozen is a biotechnology company developing antibody-based therapeutics, specifically multispecific antibodies using its proprietary SWAP platform. Its revenue is currently derived from collaboration agreements, licensing, and milestone payments from partners like Boehringer Ingelheim for these biologic candidates.
LRMR
Larimar Therapeutics
$329.31Mn
3.17
+2.92%
-6.21%
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, which is described as a recombinant fusion protein. Its core business is based on a cell penetrating peptide (CPP) technology platform to create therapies derived from biological science.
BIOA
BioAge Labs
$328.68Mn
7.18
+1.84%
+31.74%
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases using a proprietary platform based on multi-omic data. Its revenue is derived from collaboration agreements and milestones with pharmaceutical partners like Lilly and Novartis, which is characteristic of biotechnology developers.
EPRX
Eupraxia Pharmaceuticals
$328.04Mn
8.21
+2.50%
+42.78%
Eupraxia is a clinical-stage biotechnology company developing therapies derived from biological science, specifically utilizing its proprietary DiffuSphere™ microparticle system for drug delivery. Its lead candidates, EP-104GI and EP-104IAR, are currently in clinical trials (Phase 1b/2a and Phase 2b/3) for the treatment of eosinophilic esophagitis and osteoarthritis.
PRLD
Prelude Therapeutics
$312.03Mn
3.91
+0.77%
+185.40%
Prelude Therapeutics is a biotechnology company focused on discovering and developing therapies derived from biological science, specifically protein degraders and antibody-drug conjugates (ADCs). Its revenue model is based on strategic partnerships, upfront payments, and milestone payments from collaborations with partners like Incyte and AbCellera.
WHWK
Whitehawk Therapeutics
$311.65Mn
3.76
+0.53%
+95.83%
Whitehawk Therapeutics is a clinical-stage biotechnology company focused on developing antibody-drug conjugates (ADCs), which are biologic-based therapies. Its current pipeline includes candidates HWK-007, HWK-016, and HWK-206, which utilize a linker-payload platform to target tumor antigens.
BBOT
BridgeBio Oncology Therapeutics
$305.24Mn
3.81
-3.54%
-66.78%
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically targeting the RAS and PI3Kα oncogenes. Its pipeline includes investigational agents such as BBO-8520, BBO-11818, and BBO-10203, which are currently in phase 1 clinical trials.
EVMN
Evommune
$304.40Mn
8.39
-1.06%
—
Evommune is a clinical-stage biotechnology company developing therapies derived from biological science, specifically the fusion protein EVO301 which inhibits the IL 18 cytokine. Its revenue model consists of upfront payments, milestone payments, and royalties from partnerships with firms like Dermira, Maruho, and AprilBio.
ELDN
Eledon Pharmaceuticals
$299.99Mn
2.64
-0.38%
+3.94%
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, which is an engineered IgG1 antibody. Its business model focuses on biology-based drug discovery and development for indications such as kidney transplantation and ALS.
UPB
Upstream Bio
$290.29Mn
5.30
-1.12%
-69.43%
Upstream Bio is a clinical-stage biotechnology company developing verekitug, which is a monoclonal antibody. Its business model focuses on the research and development of biologic therapies for inflammatory respiratory diseases like severe asthma and COPD.
CYDY
CytoDyn
$288.44Mn
0.21
-8.70%
-19.23%
CytoDyn is a clinical-stage biotechnology company developing leronlimab, which is specifically described as a humanized monoclonal antibody. Its revenue model is based on the typical biotech structure of milestone payments, royalties, and potential future sales of biologic products.
CATX
Perspective Therapeutics
$285.22Mn
2.50
-0.40%
-25.37%
Perspective Therapeutics is a biotechnology company developing therapies derived from biological science, specifically linking the isotope Lead 212 to tumor-specific targeting peptides for cancer treatment. Its revenue model consists of upfront fees, milestone payments, and royalties from collaborations with partners like Lantheus and Bristol Myers Squibb.
EYPT
EyePoint
$281.29Mn
3.31
-8.56%
-76.44%
EyePoint is a clinical-stage biopharmaceutical company developing therapies for retinal diseases, such as DURAVYU for wet age-related macular degeneration. Its revenue model includes licensing product candidates and receiving milestone payments and royalties, which is characteristic of biotechnology developers.
IVVD
Invivyd
$280.02Mn
0.95
+2.15%
-15.18%
Invivyd is a biopharmaceutical company that researches and commercializes monoclonal antibody therapies, such as PEMGARDA, which are derived from biological science. Its revenue is generated from the sale of these biologic products and milestone payments from collaborations with Adimab.
GLSI
Greenwich LifeSciences
$272.64Mn
18.59
+2.03%
+82.97%
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing immunotherapy products, specifically GLSI-100, which utilizes the GP2 peptide and GM-CSF. These are biological components designed to elicit an immune response, fitting the description of therapies derived from biological science.
TLSI
2nd
TriSalus Life Sciences
$269.85Mn
4.39
+1.15%
-6.00%
The company is developing nelitolimod, an investigational immunotherapeutic class C Toll-like receptor 9 agonist, which is a biology-based drug candidate for future combination therapies.
SABS
SAB Biotherapeutics
$268.01Mn
3.21
-2.43%
+64.62%
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically multi-specific high potency human immunoglobulin G. Its lead candidate, SAB 142, is a biologic designed to treat autoimmune type 1 diabetes.
STRO
Sutro Biopharma
$265.72Mn
16.03
+0.31%
+82.16%
Sutro Biopharma is a clinical-stage oncology company developing antibody-drug conjugates (ADCs), which are biologic therapies. Its revenue is derived from collaboration and license agreements, milestone payments, and royalties from partners like Astellas Pharma and Merck Sharp & Dohme.
ACIU
AC Immune
$265.55Mn
2.61
+3.57%
-14.14%
AC Immune is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically active immunotherapies targeting proteinopathies. Its revenue is generated through collaboration and milestone payments from pharmaceutical partners for these biologic candidates.
GALT
Galectin Therapeutics
$260.61Mn
3.93
+0.77%
-6.87%
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically proprietary complex carbohydrates from plant-based materials. It focuses on the discovery and development of agents to inhibit galectin 3 for the treatment of fibrotic diseases and cancer.
BCYC
Bicycle Therapeutics
$259.01Mn
3.71
+0.82%
-51.25%
Bicycle Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically synthetic short peptides (Bicycle molecules). Its revenue is currently derived from collaboration and licensing arrangements with partners like Ionis and Bayer, as well as milestone payments.
MGNX
Macrogenics
$258.40Mn
4.06
+8.56%
+132.00%
MacroGenics is a biopharmaceutical company that develops antibody-based therapeutics using proprietary biological platforms like DART and TRIDENT. Its revenue is derived from the sale of biologic products, royalties, and milestone payments from collaborations with partners like Gilead.
TRDA
Entrada Therapeutics
$242.19Mn
6.22
+0.97%
+6.51%
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically nucleic acid therapeutics using its Endosomal Escape Vehicle (EEV) platform. Its revenue is currently derived from collaboration and milestone payments, such as those from Vertex Pharmaceuticals for the development of VX-670.
AKBA
2nd
Akebia Therapeutics
$241.85Mn
0.89
-1.11%
-67.16%
The company utilizes a hypoxia inducible factor platform to develop its therapies and maintains a pipeline of investigational agents for rare kidney disorders, which aligns with biotechnology-based drug discovery and development.
KROS
Keros Therapeutics
$223.65Mn
11.28
-2.93%
-29.28%
Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically engineered ligand traps and protein therapeutics. Its revenue is currently derived from collaboration and milestone payments from partners like Takeda and Hansoh for candidates such as elritercept.
CGEN
Compugen
$220.31Mn
2.33
-2.10%
+61.81%
Compugen is a clinical-stage biotechnology company that develops antibody-based therapies, such as COM701 and COM902, derived from biological science. Its revenue model is based on biologic product collaborations, milestone payments, and royalties from partners like Gilead and AstraZeneca.
QTTB
Q32 Bio
$219.09Mn
9.23
+5.25%
+375.77%
Q32 Bio is a clinical-stage biotechnology company developing biologics, specifically monoclonal antibodies like bempikibart (ADX-914) and a tissue-targeted complement inhibitor platform. Its revenue is derived from collaboration and licensing agreements with partners such as Bristol-Myers Squibb and Akebia Therapeutics, which include upfront payments and milestones.
AVXL
Anavex Life Sciences
$217.84Mn
2.35
-1.26%
-72.83%
Anavex is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting the sigma 1 receptor for CNS diseases. Its lead candidates, ANAVEX 2 73 and ANAVEX 3 71, are being developed for Alzheimer's, Parkinson's, and Rett syndrome, and the company currently generates revenue through research grants and collaborations.
PLX
Protalix BioTherapeutics
$217.54Mn
2.70
-0.37%
+25.00%
Protalix is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically recombinant therapeutic proteins produced via its ProCellEx plant cell-based expression system. Its revenue is derived from the sale of biologic products like Elelyso and Elfabrio, as well as milestone payments and royalties.
ALEC
Alector
$214.38Mn
1.92
-1.54%
-37.05%
Alector is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like nivisnebart and latozinemab. Its revenue is generated through collaboration agreements, milestone payments, and royalties from pharmaceutical partners such as GSK.
INDP
Indaptus Therapeutics
$210.93Mn
3.29
-14.55%
+10.03%
Indaptus Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically using attenuated non-pathogenic Gram-negative bacteria for immunotherapy. Its lead candidate, Decoy20, is being evaluated in clinical trials for advanced solid tumors.
FHTX
Foghorn Therapeutics
$206.67Mn
3.52
+0.57%
-29.74%
Foghorn Therapeutics is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically targeting the chromatin regulatory system. Its revenue is generated through strategic collaborations, such as the partnership with Eli Lilly, which includes upfront payments, milestones, and royalties.
CAMP
Camp4 Therapeutics
$199.92Mn
3.85
-1.79%
+25.41%
Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics, specifically antisense oligonucleotides, which are a form of oligonucleotide medicine. Its revenue is derived from collaboration and licensing agreements, such as the research collaboration with GlaxoSmithKline, which is characteristic of biotechnology developers.
CMPX
Compass Therapeutics
$199.90Mn
1.11
-1.77%
-70.94%
Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, specifically using its proprietary StitchMabs platform to create bispecific antibodies. Its revenue is derived from collaboration and milestone payments from partners like ABL Bio and Adimab, which is characteristic of the Biotechnology industry.
ORMP
Oramed Pharmaceuticals
$196.24Mn
4.75
+0.42%
+75.93%
Oramed is a biotechnology company focused on the research and development of an oral insulin capsule and a technology platform for the oral delivery of therapeutic proteins. Its core business is the development of biology-based therapies to compete with other insulin developers and pharmaceutical firms.
ALXO
Alx Oncology Holdings
$192.12Mn
1.39
+6.11%
-20.57%
Alx Oncology Holdings is a clinical-stage biotechnology company developing therapies derived from biological science, specifically the CD47 blocking fusion protein evorpacept and the EGFR targeted antibody-drug conjugate ALX2004. Its current revenue is generated through collaboration and licensing agreements with partners like Jazz Pharmaceuticals and Sanofi, which is characteristic of the H-02 classification.
TARA
2nd
Protara Therapeutics
$192.02Mn
3.25
-0.91%
-26.30%
The company also develops IV Choline Chloride, a phospholipid substrate replacement therapy for patients receiving parenteral support, which falls under the broader category of biological science-derived therapies and biopharmaceuticals.
ADAG
Adagene
$189.54Mn
3.20
+9.22%
+58.42%
Adagene is a clinical-stage biotechnology company developing antibody-based cancer immunotherapies, such as its lead candidate ADG126 (a masked anti-CTLA-4 antibody). Its revenue is derived from collaboration and milestone payments from partners like Sanofi and Exelixis, which is characteristic of the H-02 classification.
EQ
Equillium
$187.83Mn
1.68
+0.60%
+15.07%
Equillium is a biotechnology innovator developing therapies derived from biological science, specifically targeting interleukin 15 and interleukin 21. The company is currently a clinical-stage developer with preclinical candidates EQ504 and EQ302.
ACOG
2nd
Alpha Cognition
$187.26Mn
8.60
+1.53%
+29.91%
The company maintains a pre-clinical development pipeline including Progranulin and Progranulin GEMs (ALPHA-0602, ALPHA-0702, and ALPHA-0802) for neurodegenerative diseases such as ALS and SMA, which are biological-based therapies.
PYXS
Pyxis Oncology
$183.96Mn
2.90
+1.40%
+31.82%
Pyxis Oncology is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs), which are biologic therapies. Its revenue is derived from collaboration and licensing agreements with partners like Merck, Pfizer, and Biosion, as well as milestone payments.
ANTX
AN2 Therapeutics
$181.91Mn
5.01
+2.66%
+291.41%
AN2 Therapeutics is a clinical-stage biopharmaceutical company that researches and develops therapies derived from its proprietary boron chemistry platform. Its revenue model consists of licensing agreements, milestone payments, and royalties from partners like Anacor Pharmaceuticals and Brii Biosciences, which is characteristic of the Biotechnology industry.
PEPG
PepGen
$179.38Mn
2.59
+0.00%
-44.18%
PepGen is a clinical-stage biotechnology company developing oligonucleotide therapeutics, specifically using its EDO platform to create drugs like PGN EDODM1. Its business model focuses on the research and development of therapies derived from biological science to treat neuromuscular and neurologic diseases.
MDWD
MediWound
$178.79Mn
13.93
+0.65%
-22.48%
MediWound develops and commercializes biologics, specifically enzymatic therapeutics like NexoBrid, for wound and burn care. Its revenue model includes biologic product sales, royalties, and milestone payments, which aligns with the Biotechnology classification.
QNCX
Quince Therapeutics
$177.85Mn
29.00
-4.61%
-90.99%
Quince Therapeutics is a biotechnology company that developed the AIDE technology platform to encapsulate therapeutic agents within red blood cells. Its lead candidate, eDSP, was a biologic-based delivery system for dexamethasone phosphate targeting ataxia telangiectasia.
ORGO
2nd
Organogenesis Holdings
$177.57Mn
1.38
-2.13%
-67.61%
The company develops and commercializes therapies derived from biological science, specifically bioengineered skin substitutes like Apligraf and Dermagraft, as well as placental allografts and porcine collagen matrices.
CHRS
Coherus Oncology
$176.10Mn
1.14
+0.88%
-32.94%
Coherus Oncology develops and commercializes therapies derived from biological science, specifically the anti-PD-1 antibody LOQTORZI. Its revenue is generated from the sale of this biologic product and through licensing fees, milestone payments, and royalties from collaboration agreements.
XLO
Xilio Therapeutics
$175.61Mn
9.05
+0.11%
-25.08%
Xilio Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically masked bispecific antibodies, T cell engagers, and cytokine-based therapies. Its revenue is currently derived from collaboration and milestone payments from pharmaceutical partners like AbbVie and Gilead.
PRQR
ProQR Therapeutics
$173.85Mn
1.65
+0.00%
-24.66%
ProQR Therapeutics is a clinical-stage biotechnology company that develops RNA editing therapeutics using its proprietary Axiomer platform. Its revenue is derived from collaboration agreements, such as the $125 million upfront payment from Eli Lilly, and research grants for biologic-based drug discovery.
ABOS
Acumen Pharmaceuticals
$166.32Mn
2.30
+2.68%
+45.57%
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing sabirnetug (ACU193), which is a recombinant humanized monoclonal antibody. Its revenue model consists of collaboration payments, milestones, and royalties, which is characteristic of biotechnology drug developers.
TNXP
2nd
Tonix Pharmaceuticals Holding
$166.24Mn
9.90
+0.41%
-60.02%
The company maintains a broad pipeline of development-stage candidates and utilizes biological science for therapies, such as TNX-801, which is a live virus vaccine for smallpox and mpox.
VYGR
2nd
Voyager Therapeutics
$165.44Mn
2.70
+0.75%
-42.68%
The company also develops antibody candidates, such as the anti-tau antibody VY7523, which falls under the category of biological science-derived therapies.
IPHA
Innate Pharma
$159.32Mn
1.70
+0.00%
-6.59%
Innate Pharma is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically therapeutic antibodies and the ANKET platform for engaging natural killer cells. Its revenue model consists of upfront payments, milestone payments, and royalties from collaborations with biopharma partners like AstraZeneca and Sanofi.
ADCT
ADC Therapeutics
$159.30Mn
1.25
-0.79%
-68.91%
ADC Therapeutics develops and commercializes antibody drug conjugates (ADCs), which are biologics, specifically ZYNLONTA for B-cell lymphomas. Its revenue is derived from biologic product sales and licensing collaborations involving milestone payments and royalties.
MOLN
Molecular Partners Ag
$158.67Mn
3.93
-8.60%
+6.79%
Molecular Partners AG is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically using its proprietary DARPin platform to create recombinant proteins. Its revenue is generated through collaboration and milestone payments from partners like Orano Med and Eckert & Ziegler for the development of biologic product candidates.
FTH
Faeth Therapeutics
$156.71Mn
27.77
-0.82%
+190.79%
Sensei Biotherapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, including antibody-based projects like solnerstotug and SNS 102. Its revenue model relies on external financing and potential collaboration/milestone payments typical of biotech developers.
NBP
NovaBridge Biosciences
$149.78Mn
1.36
-1.45%
-60.23%
NovaBridge Biosciences is a biotechnology platform company focused on the discovery and development of therapies derived from biological science, specifically bispecific antibodies. Its pipeline includes candidates like gavastomig and uliledlimab, and it generates revenue through licensing agreements, collaboration arrangements, and milestone payments.
NGEN
Nervgen Pharma
$149.74Mn
1.88
-3.09%
-20.00%
NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG 291, which is described as a humanized peptide. Peptides are specifically listed as a biology-based therapy under the Biotechnology industry classification.
CLLS
2nd
Cellectis
$148.50Mn
1.48
+0.68%
-47.89%
The company develops biologics and generates significant revenue through licensing agreements, milestones, and royalties with partners like AstraZeneca and Allogene for the development of biologic therapies.
RANI
Rani Therapeutics Holdings
$145.99Mn
0.78
+2.63%
+59.18%
Rani Therapeutics is a clinical-stage biotherapeutics company developing oral delivery for biologics such as GLP-1/GLP-2 dual agonists, adalimumab, and ustekinumab. Its revenue is currently derived from collaboration and license agreements, including upfront payments and milestones from partners like Chugai Pharmaceutical and Celltrion.
CUE
Cue Biopharma
$143.55Mn
27.45
-12.61%
+27.26%
Cue Biopharma is a clinical-stage company developing biologics, specifically bifunctional fusion proteins and engineered biologics using its ImmunoSTAT platform. Its revenue is derived from collaboration and license agreements with partners like Boehringer Ingelheim and LG Chem, which is characteristic of biotechnology drug developers.
KRRO
Korro Bio
$139.85Mn
9.51
-0.63%
-77.78%
Korro Bio is a biopharmaceutical company developing therapies derived from biological science, specifically using RNA editing and oligonucleotides. Its pipeline includes KRRO 121 and programs for alpha 1 antitrypsin deficiency and ALS, which are characteristic of biotechnology-focused drug development.
ARMP
Armata Pharmaceuticals
$138.55Mn
3.73
-0.27%
+26.44%
Armata Pharmaceuticals is a clinical-stage biotechnology company developing therapies derived from biological science, specifically bacteriophage therapeutics. Its lead candidates, such as AP-PA02 and AP-SA02, are biologics designed to target antibiotic-resistant bacterial infections.
MSLE
Satellos Bioscience
$136.19Mn
8.81
+1.26%
+42.33%
Satellos Bioscience is a clinical-stage biotechnology company that uses its proprietary MyoReGenX platform to develop therapies for severe muscle conditions. Its lead program targets Duchenne muscular dystrophy by inhibiting the protein kinase AAK1 to promote muscle regeneration.
ENTX
Entera Bio
$132.59Mn
2.69
-1.82%
+37.95%
Entera Bio is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically oral tablet formulations of peptides and protein replacement therapies. Its pipeline includes candidates like EB613 (parathyroid hormone) and EB618 (GLP-1 glucagon agonist), and it generates funding through collaboration agreements and grants.
IFRX
InflaRx
$131.57Mn
1.82
-3.70%
+32.85%
InflaRx is a biopharmaceutical company whose primary commercial product, vilobelimab (GOHIBIC), is a monoclonal antibody used to treat SARS CoV 2 induced ARDS. The company also develops other biology-based therapies like IFX002, which is another anti-C5a antibody.
SPRB
Spruce Biosciences
$130.79Mn
47.51
-2.48%
+389.79%
Spruce Biosciences is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically TA-ERT (an enzyme replacement therapy) and SPR202 (an anti-CRH monoclonal antibody). Its revenue model is based on licensing agreements, milestone payments, and royalties from partnerships with other biotech and pharma firms.
NMRA
Neumora Therapeutics
$129.65Mn
0.69
+1.47%
-60.80%
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric and neurodegenerative disorders, such as navacaprant for major depressive disorder and NMRA-511 for Alzheimer's agitation. Its revenue model consists of milestone payments and royalties from collaborations with partners like Amgen and The Scripps Research Institute, which is characteristic of biotechnology developers.
UNCY
Unicycive Therapeutics
$129.25Mn
4.64
-1.28%
+11.81%
Unicycive Therapeutics is a clinical-stage biotechnology company developing therapies for kidney disease, specifically oxylanthanum carbonate for hyperphosphatemia and UNI 494 for acute kidney injury. Its revenue model is based on the future sale of these biologic/drug products and current licensing agreements providing milestone payments and royalties.
NRXP
NRX Pharmaceuticals
$123.86Mn
2.87
-4.01%
-11.69%
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for CNS disorders, such as NRX 100 and NRX 101, which focus on modulating the NMDA receptor. Its core business is the research and development of these biology-based drug candidates.
IBIO
iBio
$121.75Mn
1.17
-1.68%
+39.29%
iBio is a preclinical stage biotechnology company developing precision antibody therapeutics, which are biologics. Its revenue is derived from collaboration and licensing agreements, milestone payments, and royalties, specifically through its alliance with AstralBio.
TLSA
Tiziana Life Sciences
$118.10Mn
0.98
-2.97%
-53.99%
Tiziana Life Sciences is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies such as Foralumab (anti-CD3) and TZLS 501 (anti-IL 6 receptor). Its business model focuses on biology-based drug discovery and development for neurodegenerative and neuroinflammatory diseases.
COYA
Coya Therapeutics
$116.82Mn
4.98
-1.97%
-12.01%
Coya Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically biologics that enhance regulatory T cells (Tregs). Its pipeline includes COYA 302, a combination biologic utilizing a proprietary low-dose IL2 backbone.
OKUR
OnKure Therapeutics
$111.77Mn
2.76
-4.83%
+3.37%
OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines, specifically small molecule inhibitors like OKI-219. The company's core activity is biology-based drug discovery and development targeting mutant proteins in cancers.
GNLX
Genelux
$110.76Mn
2.47
-0.40%
-41.88%
Genelux is a biopharmaceutical company developing oncolytic viral immunotherapies, specifically using a modified strain of the vaccinia virus (VACV). Its revenue is derived from licensing agreements and milestone payments from Newsoara BioPharma Co Ltd for the development of its biologic candidate, Olvi Vec.
CTOR
Citius Oncology
$108.93Mn
1.03
-1.90%
-49.26%
Citius Oncology is a biopharmaceutical company that developed LYMPHIR, an engineered IL 2 diphtheria toxin fusion protein, which is a biologic therapy. Revenue is generated from the sale of this biologic product and through collaboration milestone payments and royalties.
BDTX
Black Diamond Therapeutics
$105.13Mn
1.83
-2.66%
-50.94%
Black Diamond Therapeutics is a clinical-stage biotechnology company developing MasterKey therapies, such as silevertinib and BDTX-4933, which are derived from biological science to target oncogenic mutations. Its revenue model consists of upfront payments, milestone payments, and royalties from licensing agreements, such as the $70.0 million payment from Servier Pharmaceuticals.
RFL
Rafael Holdings
$102.93Mn
2.01
+3.08%
+46.72%
Rafael Holdings is primarily a biotechnology company developing therapies derived from biological science, such as Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 and the liposomal prodrug Promitil® via LipoMedix.
PLYX
Polaryx Therapeutics
$101.69Mn
2.04
-2.39%
—
Polaryx Therapeutics is a clinical-stage biotechnology company developing therapies for rare pediatric lysosomal storage diseases. Its revenue model consists of licensing agreements, milestone payments, and royalties, which is characteristic of the H-02 classification.
MIST
Milestone Pharmaceuticals
$99.60Mn
0.80
+1.27%
-60.59%
Milestone Pharmaceuticals is a biopharmaceutical company that researches and develops therapies derived from biological science, specifically focusing on etripamil for cardiovascular conditions. Its revenue is generated from the sale of its lead biologic-based product, CARDAMYST, and potential milestone payments and royalties from collaboration partners.
PYPD
PolyPid
$96.66Mn
5.31
+1.72%
+59.46%
PolyPid is a biopharmaceutical company developing therapies derived from biological science and specialized delivery platforms, such as its long-acting GLP-1 receptor agonist and OncoPLEX for oncology. Its revenue currently comes from collaboration payments, milestones, and licensing agreements, which is characteristic of biotechnology developers.
ANIX
2nd
Anixa Biosciences
$96.49Mn
2.79
+0.36%
-18.18%
The company maintains a significant vaccine segment developing therapies for breast, ovarian, lung, colon, and prostate cancers. These vaccine programs, targeting proteins like alpha-lactalbumin, are biological therapies derived from biological science.
PMN
ProMIS Neurosciences
$95.51Mn
10.65
-5.50%
-3.18%
ProMIS Neurosciences is a clinical-stage biotechnology company developing monoclonal antibodies such as PMN310, PMN267, and PMN442. Its revenue model is based on collaboration payments, milestones, and royalties typical of biology-based drug discovery.
INO
Inovio Pharmaceuticals
$95.49Mn
1.17
-0.85%
-52.05%
Inovio is a clinical-stage biotechnology company developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. Its revenue is derived from biologic-focused activities including license fees, milestone payments, and collaborative R&D agreements with partners like ApolloBio and AstraZeneca.
RLYB
Rallybio
$90.48Mn
17.05
+2.59%
+282.29%
Rallybio is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like RLYB116 (a C5 inhibitor) and RLYB332 (a matriptase 2 inhibitor). Its current revenue is derived from collaboration agreements, licensing deals, and milestone payments from partners such as Sanofi and Johnson & Johnson.
TLPH
Talphera
$89.88Mn
1.19
+0.85%
+30.77%
Talphera is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics, specifically small molecule drug candidates like TP-0184. Its revenue model relies on collaborations, licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
ACRV
Acrivon Therapeutics
$88.27Mn
2.06
-1.90%
+13.19%
Acrivon is a clinical-stage biopharmaceutical company that researches and develops therapies derived from biological science, specifically focusing on precision medicines for cancer. Its revenue model includes licensing agreements, milestone payments, and royalties, as seen in its agreement with Eli Lilly for ACR-368.
RVRC
Revium Rx
$86.84Mn
1.43
+0.00%
+175.00%
Revium Rx is a pre-clinical stage biopharmaceutical company developing therapies derived from biological science, specifically nanoparticle-based and lipid-based delivery systems. Its product pipeline includes nano-formulations for antibiotics, oncology, and a Liposomal Protein-Loaded Technology (LPLT) platform for vaccines.
CRBP
Corbus Pharmaceuticals Holdings
$86.74Mn
6.92
-3.08%
-43.56%
Corbus is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically an antibody drug conjugate targeting Nectin 4. Its revenue model currently consists of licensing agreements, such as the one with CSPC for CRB 701, which is characteristic of biotechnology developers.
OTLK
Outlook Therapeutics
$84.78Mn
0.62
-3.12%
-41.51%
Outlook Therapeutics develops and commercializes ONS 5010 LYTENAVA, which is an ophthalmic formulation of bevacizumab, a monoclonal antibody (biologic). The company's revenue is derived from the sale of this biologic product to hospitals and clinics for the treatment of retinal diseases.
TELO
Telomir Pharmaceuticals
$82.53Mn
1.20
-2.44%
-10.45%
Telomir Pharmaceuticals is a preclinical stage biotechnology company developing therapies derived from biological science, specifically targeting epigenetic mechanisms and telomere biology. Its lead candidate, Telomir 1, is designed to address cancer, aging, and degenerative diseases through metal ion regulation and epigenetic remodeling.
ONCY
Oncolytics Biotech
$82.26Mn
0.66
-2.94%
-53.19%
Oncolytics Biotech is a clinical-stage biopharmaceutical company developing pelareorep, an oncolytic virus derived from a reovirus strain, which is a therapy derived from biological science. The company's revenue model is based on the future sale of this biologic product, as well as potential licensing fees and milestone payments from collaborators.
CRDF
Cardiff Oncology
$82.20Mn
1.20
-3.23%
-42.31%
Cardiff Oncology is a clinical-stage biotechnology company focused on the research and development of onvansertib, a highly selective PLK1 inhibitor. Its revenue model is based on clinical development milestones and potential future licensing agreements for this biologic-based drug candidate.
GANX
Gain Therapeutics
$76.71Mn
1.77
-0.56%
-2.21%
Gain Therapeutics is a biotechnology company that researches and develops therapies derived from biological science, specifically using its Magellan platform to design allosteric regulators (STARs). Its lead candidate, GT 02287, and other preclinical programs for Gaucher disease and Alzheimer's are typical of biology-based drug discovery and development.
RTGN
2nd
RetinalGenix Technologies
$75.19Mn
3.99
+0.00%
+12.71%
The company is developing pharmaceutical therapies, specifically RTG-2023 for dry AMD and RTG-2024 for Alzheimer's syndrome dementia, which fall under the research and development of therapies for systemic and ophthalmic diseases.
FBIO
Fortress Biotech
$72.28Mn
2.17
-4.82%
-44.36%
Fortress Biotech operates as a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically through its subsidiary Mustang Bio, which develops CAR T-cell therapies for oncology and rare diseases. The company's revenue model includes biologic product sales, milestone payments, and royalties from its diversified portfolio of biotech assets.
MAIA
MAIA Biotechnology
$71.76Mn
1.18
-2.48%
-26.25%
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing ateganosine, a targeted immunotherapy for cancer. Its revenue model currently relies on collaboration and milestone payments from partners like Regeneron and BeOne Medicines, which is characteristic of biotechnology developers.
KZIA
Kazia Therapeutics
$70.77Mn
9.60
+0.31%
+28.51%
Kazia Therapeutics is a biotechnology company focused on the research and development of oncology therapies, specifically Paxalisib and EVT801. Its revenue model is based on the future commercialization of these biologic-focused drug candidates through product sales, licensing agreements, milestone payments, and royalties.
ALDX
Aldeyra Therapeutics
$69.97Mn
1.16
-4.13%
-77.74%
Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases, such as reproxalap for dry eye disease. Its revenue model currently relies on collaboration payments, such as the option and extension fees received from AbbVie, which is characteristic of clinical-stage biotech developers.
RNXT
2nd
RenovoRx
$69.94Mn
1.55
-6.63%
+31.36%
The company is developing a drug-device combination candidate, intra arterial gemcitabine delivered via RenovoCath (IAG), which is currently in a Phase III trial for locally advanced pancreatic cancer.
SPRO
Spero Therapeutics
$69.19Mn
1.19
-3.25%
-37.37%
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases, such as tebipenem HBr. Its revenue model consists of license agreements, milestone payments, and royalties from partners like GlaxoSmithKline, which is characteristic of biotechnology developers.
CSBR
2nd
Champions Oncology
$68.06Mn
4.89
-0.20%
-23.35%
The company pursues internal drug discovery and development programs focused on targeted therapy, immune oncology, and cell therapy to create novel oncology therapeutics for partnership or outlicensing.
CNTB
Connect Biopharma Holdings
$68.01Mn
1.08
+0.00%
-18.18%
Connect Biopharma is a clinical-stage biopharmaceutical company developing rademikibart, which is specifically described as a monoclonal antibody. Its revenue model currently consists of license and collaboration agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
KLRS
Kalaris Therapeutics
$67.84Mn
2.85
-2.40%
-55.12%
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing TH103, which is described as a fully humanized recombinant fusion protein. This falls under the biotechnology category as it is a therapy derived from biological science (recombinant proteins) aimed at treating retinal diseases.
XBIT
XBiotech
$65.55Mn
2.15
-0.92%
-20.07%
XBiotech researches and develops monoclonal antibodies, which are biologics, for treating oncology, rheumatology, and infectious diseases. Its revenue model includes biologic product sales, licensing agreements, and milestone payments, such as the $750 million sale of Bermekimab.
ASBP
Aspire Biopharma Holdings
$63.83Mn
8.50
+2.16%
-32.11%
Aspire is an early-stage biopharmaceutical company developing a sublingual delivery platform for drug candidates, including a high-dose aspirin formulation for myocardial infarction prevention. Its business model includes potential revenue from the sale of these approved drug candidates and future licensing or collaboration agreements.
ATHE
Alterity Therapeutics
$63.44Mn
3.50
-4.63%
-11.17%
Alterity Therapeutics is a biotechnology company focused on the discovery and development of therapeutic candidates for neurodegenerative disorders, such as its lead candidate ATH434. Its revenue model includes licensing agreements, research collaborations, and grant funding, which is characteristic of clinical-stage biotech developers.
MREO
Mereo BioPharma
$59.09Mn
0.37
+0.00%
-81.12%
Mereo BioPharma is a biopharmaceutical company developing therapies for rare diseases, including setrusumab and alvelestat. Its revenue model currently consists of upfront payments, milestone payments, and royalties from collaborations with partners like Ultragenyx and Feng Biosciences, which is characteristic of biotechnology developers.
ALGS
Aligos Therapeutics
$57.79Mn
5.54
+0.54%
-42.41%
Aligos Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically oligonucleotide candidates and small molecules for liver diseases and viral infections. Its revenue is currently derived from collaborations, licensing agreements, and milestone payments, which is characteristic of the H-02 classification.
APTN
2nd
Adaptin Bio
$56.76Mn
6.27
+0.00%
—
The company utilizes recombinant technology and targets the immune system to develop therapies for CNS disorders and autoimmune diseases, which falls under the broader scope of biotechnology-based drug discovery.
NMAD
Nomad Power Solutions
$55.50Mn
3.60
+0.56%
-30.64%
Lixte is a clinical-stage biopharmaceutical company developing cancer therapies, specifically inhibitors of protein phosphatase 2A such as LB 100. Its business model focuses on biology-based drug discovery and development with expected revenue from licensing, partnerships, and future product sales.
INMB
2nd
Inmune Bio
$55.31Mn
2.00
-1.48%
-5.21%
The company's XPro segment develops XPro1595, a next-generation protein therapeutic designed to neutralize soluble tumor necrosis factor for Alzheimer disease, which fits the description of recombinant protein medicines under biotechnology.
HRTX
Heron Therapeutics
$55.06Mn
0.29
+0.00%
-77.17%
Heron Therapeutics is described as a biotechnology company that leverages advanced science and proprietary Biochronomer technology to develop therapies. Its revenue is derived from the sale of biologic-style innovative products like ZYNRELEF and CINVANTI, which are differentiated through unique formulations and delivery mechanisms.
EXOZ
2nd
Exozymes
$54.48Mn
5.87
-5.93%
-59.52%
The company develops biological solutions to create active pharmaceutical ingredients and pharmaceutical derivatives for conditions like diabetes and obesity. It focuses on the research and development of these biology-based therapies through its Nutraceutical and Pharmaceutical Development segment.
RNTX
Rein Therapeutics
$48.30Mn
0.72
-4.00%
-37.39%
Rein Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically peptides like LTI-03 (derived from caveolin 1 protein) and proenzymes like LTI-01. Its revenue model is based on collaboration and milestone payments, such as the $5.0 million upfront payment from Taiho Pharmaceutical.
LITS
Lite Strategy
$47.81Mn
1.36
-5.56%
-46.46%
Lite Strategy is a pharmaceutical company focused on developing novel cancer therapies, specifically targeting oncology through candidates like voruciclib (a CDK9 inhibitor) and zandelisib (a PI3Kδ inhibitor). Its revenue model is based on the biotechnology standard of licensing agreements, milestone payments, and royalties from pharmaceutical partners.
TIL
Instil Bio
$47.75Mn
7.04
-1.81%
-61.88%
Instil Bio is a clinical-stage biopharmaceutical company developing bispecific antibodies, specifically AXN-2510/IMM2510, which is a biologic therapy derived from biological science targeting PD-L1 and VEGF for oncology.
SCYX
Scynexis
$45.97Mn
4.62
+5.24%
-45.00%
Scynexis is a biotechnology company that researches and develops therapies derived from biological science, specifically its proprietary fungerp platform of triterpenoid compounds. Its revenue model is based on licensing agreements, milestone payments, and royalties from partners like GSK and Merck for the commercialization of its biologic-based antifungal candidates.
DWTX
Dogwood Therapeutics
$45.74Mn
1.36
+0.00%
-82.81%
Dogwood Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically synthetic peptides like the SP16 program and tetrodotoxin derivatives for the Halneuron program. The company is in the development stage with no product revenue, relying on grants and licensing agreements to fund its clinical-stage pipeline.
HOWL
Werewolf Therapeutics
$45.20Mn
0.93
-3.12%
-57.53%
Werewolf Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically conditionally activated cytokines (IL-2, IL-12, IL-21, etc.) and T-cell engagers. Its revenue is currently derived from collaboration and licensing agreements, such as the one with Jazz Pharmaceuticals for JZP898, which is typical for clinical-stage biotechnology developers.
PDSB
PDS Biotechnology
$43.06Mn
0.77
-3.75%
-23.76%
PDS Biotechnology is a clinical-stage company developing immunotherapies and vaccines derived from biological science, specifically using its Versamune and Infectimune platforms. Its pipeline includes biologic candidates like PDS0101 for HPV-related cancers and PDS0202 for influenza.
BDRX
Biodexa Pharmaceuticals
$42.96Mn
0.68
+0.00%
-97.97%
Biodexa is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically utilizing nanoparticle delivery and molecular glue technology. Its pipeline includes candidates like MTX240 and eRapa for gastrointestinal cancers and type 1 diabetes, and it generates revenue from collaboration milestones and licensing payments.
SY
2nd
So-Young International
$41.47Mn
2.69
-0.37%
-32.41%
The company develops, produces, and distributes injectable aesthetic products, which fall under the category of biological or specialty therapies for medical aesthetics.
FLNA
Filana Therapeutics
$41.06Mn
0.85
+13.33%
-72.93%
Filana Therapeutics is a clinical-stage biotechnology company researching and developing simufilam, a proprietary small-molecule therapy for central nervous system disorders. Its business model relies on collaboration agreements, research grants, and the development of a novel molecular target (filamin A) to create new therapies.
ELTX
Elicio Therapeutics
$40.52Mn
1.85
+0.54%
-82.93%
Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies derived from biological science, specifically using its Amphiphile AMP technology to generate T cell responses. Its lead candidate, ELI-002 7P, and other programs targeting BRAF and TP53 are biology-based drug discovery efforts.
IMA
ImageneBio
$39.56Mn
4.64
-1.69%
-39.74%
ImageneBio is a clinical-stage biopharmaceutical company developing IMG-007, which is a monoclonal antibody. Monoclonal antibodies are specifically listed as therapies derived from biological science under the Biotechnology industry.
HURA
TuHURA Biosciences
$39.01Mn
2.09
-0.48%
-15.38%
TuHURA Biosciences is a clinical-stage biotechnology company developing therapies derived from biological science, including the TBS-2025 VISTA-inhibiting antibody and a DOR-targeted antibody-drug conjugate platform. Its revenue model is typical of biotech, consisting of licensing fees, milestone payments, and collaborative research funding from partners like Merck.
PTN
Palatin Technologies
$37.48Mn
9.58
-5.15%
+51.82%
Palatin is a biopharmaceutical company focused on developing therapies derived from biological science, specifically MC4R and MC1R agonist peptides. Its revenue model relies on biologic product sales, licensing agreements, and milestone payments from partners like Cosette and Boehringer Ingelheim.
PTCHF
PureTech Health
$37.22Mn
1.54
+0.00%
-0.65%
PureTech Health is a biopharmaceutical company that researches and develops therapies derived from biological science, such as the LYT 100 and LYT 200 programs. Its revenue model is based on biotechnology-typical streams, including upfront fees, milestone payments, and royalties from licensing agreements with partners.
ATNM
Actinium Pharmaceuticals
$37.10Mn
1.18
-0.84%
-27.16%
Actinium is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically radioconjugates and antibody-based therapeutics like Actimab-A and ATNM-400. Its revenue model is based on the development of these biologic product candidates, strategic partnerships, and potential milestones.
ELUT
2nd
Elutia
$35.87Mn
0.81
-1.22%
-12.90%
The company develops therapies derived from biological science, specifically human acellular dermal matrices (SimpliDerm) and porcine small intestinal submucosa extracellular matrices, which are biologic scaffolds used in reconstructive surgery.
IMMP
Immutep
$35.63Mn
4.88
+1,776.92%
+172.63%
Immutep is a biotechnology company focused on developing LAG3-related immunotherapies, including monoclonal antibodies and the lead candidate eftilagimod alfa. Its revenue model is based on licensing agreements, milestone payments, and royalties from partners like Novartis and EOC Pharma.
KAPA
Kairos Pharma
$35.60Mn
1.71
-2.29%
-78.19%
Kairos Pharma is a clinical-stage biopharmaceutical company developing antibody drug candidates and therapies derived from biological science to treat various cancers. Its pipeline includes internally discovered molecules that modulate immune response, which aligns with the biotechnology classification for biology-based drug discovery.
EDSA
Edesa Biotech
$35.16Mn
3.65
-8.98%
+48.98%
Edesa Biotech is a biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like EB06 for vitiligo and EB05 (paridiprubart) for acute respiratory distress syndrome. Its revenue model currently relies on government grants and funding awards while it advances these biologic candidates through clinical development.
MCRB
Seres Therapeutics
$34.59Mn
3.52
+0.00%
-81.17%
Seres Therapeutics develops live biotherapeutic products (LBPs), which are defined consortia of bacteria, fitting the description of therapies derived from biological science. Its pipeline includes candidates like SER-155 and SER-603, and it generates revenue from the sale of its biologic product VOWST to Nestlé Health Science.
APLM
Apollomics
$34.47Mn
23.84
+6.29%
+29.35%
Apollomics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like APL-501 (anti-PD1) and APL-502 (anti-PDL1). Its revenue model is based on collaboration and milestone payments from partners such as Genor and CTTQ for these immunooncology programs.
BETRF
BetterLife Pharma
$33.42Mn
0.22
-8.33%
+266.67%
BetterLife Pharma is a biopharmaceutical company focused on the research and development of therapies derived from biological science, specifically interferon alpha 2b based products (MM-001 and MM-003). The company is a clinical-stage developer with no current revenue, which aligns with the H-02 classification for biotechnology-focused drug discovery.
SER
Serina Therapeutics
$33.26Mn
2.03
-5.58%
-58.49%
Serina Therapeutics is a clinical-stage biotechnology company developing therapies for neurological diseases, specifically targeting Parkinson's disease. Its revenue model relies on licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
TAOX
TAO Synergies
$32.51Mn
4.35
-1.81%
-30.73%
TAO Synergies is a biopharmaceutical company developing a therapeutic platform based on Bryostatin 1 for Alzheimer's disease and related cognitive disorders. Its core operational focus is on biology-based drug discovery and development, specifically targeting protein kinase C epsilon (PKCε) activation.
NNVC
Nanoviricides
$32.25Mn
1.49
+4.20%
+4.93%
NanoViricides is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically using a nanomedicine platform to create drugs that mimic host cell receptors. Its pipeline includes biologic-based candidates like NV-387 for broad-spectrum antivirals and NV-HHV-1 for herpesvirus infections.
CNTX
Context Therapeutics
$30.32Mn
0.33
-5.71%
-65.98%
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies, which are recombinant proteins. Its revenue is derived from collaboration and licensing agreements, such as the $11 million upfront payment from BioAtla for the CT 202 asset.
BRNS
Barinthus Biotherapeutics
$30.23Mn
0.74
+0.00%
-33.33%
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies derived from biological science, specifically using its proprietary SNAP-TI platform of synthetic, self-assembling nanoparticles. Its pipeline includes candidates like VTP-1000 for celiac disease and VTP-300 for chronic hepatitis B, and it generates value through platform development and strategic collaborations.
BCTX
BriaCell Therapeutics
$30.16Mn
4.16
-3.70%
-61.59%
BriaCell is a clinical-stage biotechnology company developing immunotherapies derived from biological science, specifically whole-cell immunotherapies like Bria-IMT™ and antibody-based programs through BriaPro Therapeutics. Its revenue model consists of licensing agreements, collaborative R&D arrangements, and government grants typical of pre-revenue biotech developers.
ATYR
aTYR PHARMA
$29.43Mn
0.30
-3.23%
-62.50%
aTyr Pharma is a clinical-stage biotechnology company developing therapies derived from biological science, specifically protein domains from human tRNA synthetases. Its lead candidate, efzofitimod, is a biologic, and the company generates revenue through collaboration and milestone payments from partners like Kyorin Pharmaceutical.
RAPH
Raphael Pharmaceutical
$28.25Mn
1.40
+0.00%
+536.36%
The company is a drug research and development firm focused on the discovery and clinical development of therapies derived from biological science, specifically cannabinoid-based formulas for rheumatoid arthritis and asthma. Its revenue model is based on licensing agreements, milestone payments, and royalties from future sales of these biologic drug candidates.
KYNB
Kyntra Bio
$27.94Mn
6.90
-0.58%
-43.95%
Kyntra Bio is a biopharmaceutical company developing therapies derived from biological science, specifically FG-3246, which is an antibody drug conjugate. Its revenue model includes collaboration payments, milestones, and royalties from partners like Astellas and AstraZeneca for the development of roxadustat.
ABVC
Abvc Biopharma
$27.06Mn
1.05
-7.08%
-65.91%
ABVC is an early-stage biotechnology company developing a pipeline of novel botanical drugs for CNS and oncology indications, including candidates for major depressive disorder and pancreatic cancer. Its revenue model involves advancing these biological assets through clinical trials to outlicense intellectual property rights to larger pharmaceutical partners.
NXTC
NextCure
$26.97Mn
5.08
+0.00%
-12.26%
NextCure is a clinical-stage biopharmaceutical company developing antibody drug conjugates (ADCs), which are biologic therapies. Its revenue is derived from collaboration and milestone payments, such as the $12 million upfront payment from Zaiming, and potential royalties on biologic product sales.
BHST
Bioharvest Sciences
$26.70Mn
1.45
-0.68%
-85.44%
Bioharvest Sciences is a biotechnology company that uses its proprietary Botanical Synthesis Platform to research, develop, and commercialize therapies and active ingredients derived from biological science (plant cells). Its core business is based on biology-based discovery and development to produce high-concentration active molecules.
IGC
IGC Pharma
$26.67Mn
0.27
-3.57%
-35.71%
IGC Pharma is a biopharmaceutical company focused on developing therapies for Alzheimer's disease and CNS disorders, with a lead candidate, IGC AD1, in Phase 2 clinical trials. Its core business involves biology-based drug discovery and development, including the use of IGF-based molecules and tau pathology targets.
VICP
Vicapsys Life Sciences
$25.57Mn
0.79
-7.06%
-55.37%
Vicapsys Life Sciences is a pre-clinical stage developer of therapies derived from biological science, specifically using proprietary derivatives of the chemokine CXCL12. Its core product line, VICAPSYN™, is designed to create an immuno-protective microenvironment for transplantation and stem-cell applications.
INAB
2nd
In8Bio
$24.14Mn
1.24
+3.33%
-45.13%
The company also develops gamma-delta T cell engagers (TCEs), such as INB-619, which are recombinant proteins/biologics designed to activate T cell subsets for B-cell-driven autoimmune diseases and oncology.
GRDX
GridAI Technologies
$23.71Mn
3.43
+0.00%
-30.85%
The company's biotechnology segment focuses on developing oral non-systemic biologic therapies, specifically citing Adrulipase for exocrine pancreatic insufficiency. This aligns with the development of therapies derived from biological science.
CLRB
Cellectar Biosciences
$22.38Mn
1.83
+1.67%
-66.17%
Cellectar Biosciences is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically using a proprietary phospholipid ether drug conjugate platform. Its lead programs, such as CLR125 and CLR225, are biology-based drug candidates for treating cancer, and the company generates revenue through collaborations and grants typical of biotechnology developers.
EVAX
Evaxion A
$20.76Mn
3.24
-2.99%
-14.74%
Evaxion A/S is a biotechnology company that researches and develops vaccines for cancer and infectious diseases, such as the EVX B3 candidate. Its revenue model is based on biologic product development, including licensing agreements, milestone payments, and royalties from partners like Merck Sharp and Dohme.
VRXA
Veraxa Biotech AG - Post de-SPAC
$19.83Mn
1.37
-2.84%
-86.89%
Veraxa Biotech is a biotechnology company focused on the research and development of antibody-based therapeutics, such as bispecific T-cell engaging antibodies (BiTAC-TCE). Its revenue is derived from collaboration payments, milestones, and licensing agreements related to its biologic drug candidates like VX-A901 and VX-A902.
NCNA
NuCana
$19.14Mn
1.29
+0.78%
-66.32%
NuCana is a biotechnology company focused on the research and development of therapies. While the provided profile is lean on specific product names, the company's name and operational history as a clinical-stage developer listed on Nasdaq align with the H-02 Biotechnology classification for biology-based drug discovery.
ADIL
Adial Pharmaceuticals
$18.67Mn
4.04
-4.27%
-51.03%
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04, a therapeutic for alcohol use disorder. Its revenue model is based on the future sale of this biologic-based drug candidate and potential milestone payments and royalties from collaboration agreements, such as its framework agreement with Molteni Farmaceutici.
JSPR
Jasper Therapeutics
$17.69Mn
0.63
+3.28%
-74.70%
Jasper Therapeutics is a clinical-stage biotechnology company developing briquimimab, which is specifically described as a monoclonal antibody. Its revenue model currently consists of milestone payments and royalties from licensing agreements, such as its partnership with Amgen.
RKTO
Rocket One
$17.16Mn
0.74
-3.90%
-55.15%
Hoth Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, such as the HT-004 exon-skipping oligonucleotide approach and the HT-VA glial cell line derived neurotrophic factor. Its revenue model currently relies on collaboration and milestone payments typical of biotechnology developers.
DYAI
Dyadic International
$17.13Mn
0.47
+11.90%
-59.83%
Dyadic is a biotechnology company that develops and commercializes recombinant proteins and enzymes using microbial expression platforms. Its C1 platform specifically supports the production of complex biologics such as vaccines and antibodies.
COCP
Cocrystal Pharma
$16.68Mn
1.21
+3.42%
+0.83%
Cocrystal Pharma is a clinical-stage biotechnology company that researches and develops small molecule antiviral therapies for influenza, norovirus, and coronavirus. Its revenue is currently derived from collaboration and licensing agreements, such as its partnership with Merck Sharp & Dohme Corp.
KRSA
Korsana Biosciences
$16.27Mn
30.83
-0.55%
+88.22%
Cyclerion is a biopharmaceutical company focused on developing therapies for neuropsychiatric disorders, specifically its candidate CYC 126 for treatment-resistant depression. Its current revenue is derived from licensing agreements and milestone payments associated with its sGC portfolio, such as the agreement with Akebia for praliciguat.
KTTA
Pasithea Therapeutics
$16.04Mn
0.48
-4.00%
-33.33%
Pasithea Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of innovative treatments, specifically next-generation MEK inhibitors. Its lead candidate, PAS 004, is designed to treat RASopathies and MAPK pathway driven tumors, which aligns with the research and development of therapies derived from biological science.
QNTM
Quantum Biopharma
$15.40Mn
3.96
+2.86%
-75.54%
Quantum BioPharma is a biopharmaceutical company focused on researching and developing therapies for neurodegenerative and metabolic disorders, specifically its drug candidate Lucid MS for multiple sclerosis. Its revenue model includes royalty payments from licensing agreements for its unbuzzd™ products.
CNSY
Cerenome
$14.77Mn
2.02
+1.51%
-90.27%
Plus Therapeutics develops radiopharmaceuticals derived from biological science, specifically nanoliposome encapsulated radionuclides like rhenium (186 Re) obisbemeda and 188 RNL BAM. The company's business model includes clinical-stage development, milestone payments, and potential future sales of these biologic-based therapies.
HIND
Vyome Holdings
$14.25Mn
2.03
-0.49%
-62.13%
Vyome Holdings is primarily a clinical-stage company developing biological and specialty therapies such as VT-1953 for malignant fungating wounds and VT-1908 for anterior uveitis. Its core business focus is on its biotechnology segment, which involves drug development, preclinical and clinical studies, and regulatory advancement for these candidates.
ADIA
2nd
Adia Nutrition
$14.16Mn
0.15
+25.00%
+200.00%
Through Adia Labs, the company processes and sells biologic products derived from perinatal tissues, such as AdiaVita and AdiaLink, to other healthcare providers.
LTRN
Lantern Pharma
$13.91Mn
1.09
-10.66%
-75.99%
Lantern Pharma is a biotechnology company that researches and develops cancer therapies, including small-molecule candidates (LP-300, LP-184, LP-284) and antibody-drug conjugates. Its revenue is derived from research collaborations, licensing agreements, and milestone payments, which is characteristic of clinical-stage biotech developers.
LSTA
Lisata Therapeutics
$13.68Mn
1.50
-5.06%
-40.71%
Lisata Therapeutics is a clinical-stage biotechnology company developing certepetide, a proprietary internalizing RGD peptide. Its revenue model is based on collaboration payments, milestones, and royalties typical of biotech developers.
VTGN
Vistagen Therapeutics
$13.31Mn
0.30
+11.11%
-91.53%
Vistagen is a biopharmaceutical company developing pherines, which are biological-based product candidates for conditions like social anxiety and major depressive disorder. Its revenue is currently derived from licensing and collaboration agreements, such as those with AffaMed Therapeutics and Fuji Pharma, which is characteristic of clinical-stage biotechnology developers.
BFRG
BullFrog AI Holdings
$12.24Mn
0.66
-1.49%
-52.17%
BullFrog AI Holdings is a biotechnology company that develops therapies and rescues drug assets, such as a siRNA targeting Beta2 spectrin and an improved mebendazole formulation. Its revenue model includes outlicensing these rescued assets for upfront payments, milestones, and royalties.
CMMB
Chemomab Therapeutics
$11.80Mn
1.64
-24.07%
-38.11%
Chemomab Therapeutics is a clinical-stage biotechnology company developing nebokitug, which is a humanized monoclonal antibody. Its business model focuses on the research and development of biologic therapies for fibrotic and inflammatory diseases, with potential revenue from future product sales, milestones, and royalties.
PHIO
Phio Pharmaceuticals
$11.73Mn
1.01
+0.00%
-57.20%
Phio Pharmaceuticals is a clinical-stage biotechnology company developing therapies derived from biological science, specifically using its proprietary INTASYL small interfering RNA (siRNA) gene silencing technology. Its lead programs, such as PH 762 and PH 894, are biology-based drug candidates targeting immune checkpoint proteins to treat cancers like melanoma and Merkel cell carcinoma.
BIVI
Biovie
$11.62Mn
1.54
-4.35%
-19.37%
Biovie is a clinical-stage biotechnology company researching and developing therapies for neurological and liver diseases. Its lead programs, such as bezisterim and BIV201, are currently in preclinical and clinical development stages, which is the core activity of the Biotechnology industry.
DARE
Dare Bioscience
$11.38Mn
0.75
-3.85%
-64.11%
Dare Bioscience is a biopharmaceutical company that develops therapies for women's health, including the Phase 3 study of Ovaprene and the development of DARE to PLAY. Its current revenue is primarily derived from royalty and milestone payments from its licensing agreement with Organon for XACIATO.
LPCN
Lipocine
$11.33Mn
2.09
-0.48%
-25.62%
Lipocine is a biopharmaceutical company that researches and develops therapies derived from biological science, specifically focusing on oral delivery of neuroactive steroids and hormone replacement therapies. Its revenue model is based on licensing agreements, milestone payments, and royalties for products like TLANDO, which is characteristic of biotechnology developers.
SCNX
2nd
Scienture Holdings
$11.09Mn
0.27
-3.57%
-67.86%
The company is developing a biosimilar product candidate for thrombosis, which involves the commercialization of therapies derived from biological science as described in the H-02 biotechnology category.
MTVA
MetaVia
$10.98Mn
1.67
+0.60%
-83.88%
MetaVia is a clinical-stage biotechnology company developing therapies derived from biological science, specifically dual agonists like DA-1726 (GLP-1 and glucagon receptors) and GPR119 agonists like vanoglipel. Its business model relies on the research and development of these biologic-based candidates for MASH and obesity, with potential revenue from milestone payments and royalties.
INTS
Intensity Therapeutics
$10.75Mn
3.65
-3.95%
-40.36%
Intensity Therapeutics is a clinical-stage biotechnology company developing localized cancer therapies, specifically INT230-6, using its proprietary DfuseRx platform. Its revenue model consists of research funding, collaboration agreements, and milestone payments from partners like Merck and Bristol Myers Squibb.
TOVX
Theriva Biologics
$10.10Mn
0.22
-4.35%
-45.00%
Theriva Biologics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically an oncolytic adenovirus platform for treating solid tumors. Its revenue model consists of licensing agreements, milestone payments, and royalties, such as those from the Rasayana License Agreement for SYN 020.
AIMD
2nd
Ainos
$9.82Mn
1.33
-0.75%
-61.78%
The company develops VELDONA, a low dose oral interferon alpha formulation designed to treat rare autoimmune and infectious diseases, which falls under biotechnology-based drug development.
GTBP
GT Biopharma
$9.57Mn
6.80
-1.31%
+1,072.41%
GT Biopharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically fusion protein immune cell engagers. Its focus on immuno-oncology products and the use of proprietary protein platforms for targeting cancer cells aligns with the Biotechnology industry.
APUS
Apimeds Pharmaceuticals US
$9.51Mn
6.30
-14.40%
-66.84%
The company's primary business is the development of Apitox, a purified bee venom-based therapy derived from biological science for inflammation and pain management. It is described as a clinical-stage biopharmaceutical company targeting knee osteoarthritis and multiple sclerosis.
IMRN
Immuron
$9.36Mn
1.16
+0.00%
-39.58%
Immuron is a biopharmaceutical company that develops therapies derived from biological science, specifically using a proprietary platform to produce polyclonal antibodies from bovine colostrum. The company is advancing drug candidates like IMM 124E and IMM 529 for the treatment of infectious diseases.
MDCX
Medicus Pharma
$9.03Mn
0.15
+0.00%
-94.02%
Medicus Pharma is a clinical-stage biotechnology company developing therapies such as Teverelix (a GnRH antagonist) and doxorubicin-containing microneedle arrays. Its revenue model is based on potential future out-licensing deals, strategic partnerships, and milestone payments associated with these biological and therapeutic candidates.
ALZN
Alzamend Neuro
$8.35Mn
1.73
-5.46%
-26.69%
Alzamend Neuro is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically ALZN002, which is a cell-based therapeutic vaccine using mutant peptide sensitized cells. The company's core business is the research and development of these biology-based drug candidates for neurodegenerative and neuropsychiatric disorders.
XCUR
Exicure
$7.90Mn
1.24
+1.64%
-68.21%
Exicure is a biotechnology company that historically developed nucleic acid therapies and currently manages a collaboration with GPCR Therapeutics for clinical trials involving GPC 100 for blood cancer patients. Its revenue and strategic focus are derived from biotechnology intellectual property, licensing agreements, and the development of biologic-based therapies.
OSTX
OS Therapies
$7.83Mn
1.64
-1.20%
-18.41%
OS Therapies is a clinical-stage biopharmaceutical company developing immunotherapies and antibody drug conjugate platforms, which are biology-based therapies. Its lead candidate targets the HER2 antigen to elicit an immune response, fitting the description of biotechnology-focused drug discovery and development.
RDHL
2nd
RedHill Biopharma
$7.53Mn
0.51
+2.00%
-78.21%
The company maintains a pipeline of clinical-stage therapeutic candidates for Crohn's disease, prostate cancer, and viral infections. It generates revenue from collaboration and licensing agreements, including upfront and milestone payments, which is characteristic of biotechnology developers.
SKYE
Skye Bioscience
$7.07Mn
1.61
-3.59%
-94.81%
Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, which is described as a peripherally restricted negative allosteric modulating antibody. Its revenue model consists of collaboration agreements, licensing deals, and potential milestone payments, which is characteristic of biology-based drug discovery.
PLRZ
2nd
Polyrizon
$7.05Mn
10.36
-3.81%
+52.80%
The company's Trap and Target (T&T) platform is designed for the sustained release of active pharmaceutical ingredients, such as corticosteroids and benzodiazepines, through intranasal delivery, which aligns with biotechnology-based drug delivery development.
KALA
Kala Bio
$6.88Mn
0.45
-6.25%
-99.56%
Kala Bio is described as a biopharmaceutical company that retains commercial rights to a mesenchymal stem cell secretome platform and biologics assets like KPI 012 and KPI 014. Its primary business focus, as detailed in its Biologics segment, is the monetization of these biology-based drug candidates through licensing or sale.
BOLT
Bolt Biotherapeutics
$6.88Mn
3.57
-2.19%
-32.13%
Bolt Biotherapeutics is a biotechnology company developing therapies derived from biological science, specifically its Boltbody™ Immune Stimulating Antibody Conjugate (ISAC) platform. Its revenue is generated through collaboration agreements, milestone payments, and research funding from partners like Genmab A/S and Innovent Biologics.
OSRH
OSR Health
$6.58Mn
0.20
-9.09%
-61.54%
The company's primary growth drivers are its subsidiaries Vaximm and Darnatein, which develop biological therapies. Vaximm focuses on oral T cell immunotherapies using a bacterial platform, and Darnatein creates design augmented biologics for bone and cartilage regeneration.
NRSN
NeuroSense Therapeutics
$6.49Mn
5.09
-26.76%
+307.20%
NeuroSense Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of therapies for neurodegenerative diseases. Its lead candidate, PrimeC, and its Parkinson's candidate, StabiliC, are developed using biological science to target disease-related pathways and biomarkers.
IMNN
Imunon
$6.44Mn
1.38
-2.13%
-73.36%
The provided profile contains no operational details, products, or services. However, based on the company name 'Imunon' and the mandatory requirement to assign a primary industry within the Healthcare sector, H-02 is the most plausible fit for a company focused on immunology-based biotechnology, though the text provides no specific evidence.
SNGX
Soligenix
$6.06Mn
0.38
+0.00%
-65.77%
Soligenix is a biopharmaceutical company developing therapies derived from biological science, including synthetic hypericin for photodynamic therapy and IDR technology for immune modulation. Its revenue is currently derived from government grants, contracts, and licensing/royalty payments from partners like SciClone, which is characteristic of clinical-stage biotechnology developers.
ENVB
Enveric Biosciences
$5.86Mn
1.49
-0.67%
-81.14%
Enveric Biosciences is a biotechnology company that researches and develops therapies derived from biological science, specifically focusing on neuroplastogenic therapeutics for psychiatric and neurological disorders. Its lead candidate, EB 003, and its proprietary drug discovery platform are central to its business model of biology-based drug discovery.
PULM
2nd
Pulmatrix
$5.81Mn
1.59
-2.45%
-65.13%
The company's iSPERSE platform is explicitly described as being capable of formulation with biologics in addition to small molecules. This capability to develop biology-based therapies places it within the biotechnology scope.
XBIO
Xenetic Biosciences
$5.46Mn
2.33
-2.51%
-28.09%
Xenetic Biosciences is a biopharmaceutical company developing immuno-oncology therapies, specifically a systemic DNase therapy for pancreatic and colorectal carcinoma. Its revenue model includes royalty payments from the PolyXen drug delivery platform and anticipated milestone payments from research collaborations.
CLGN
CollPlant Biotechnologies
$4.95Mn
3.87
-8.94%
-87.48%
CollPlant develops therapies and materials derived from biological science, specifically recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants. Its revenue model includes the sale of biologic products, milestone payments, and royalties from collaborations, such as its agreement with AbbVie for dermal fillers.
LIMN
Liminatus Pharma
$4.78Mn
4.27
+3.39%
-94.89%
Liminatus Pharma is a pre-clinical stage biopharmaceutical company developing IBA101, a humanized anti-CD47 monoclonal antibody. Its business model focuses on the research and development of biologic therapies derived from biological science to treat cancer.
SHPH
2nd
Shuttle Pharmaceuticals Holdings
$4.11Mn
4.11
+2.49%
-89.18%
The company identifies as a pharmaceutical company focused on drug discovery and development, intending to derive income from the eventual commercialization of drug candidates that emerge from its discovery pipeline.
GRI
GRI Bio
$3.79Mn
2.10
+2.44%
-96.21%
GRI Bio is a clinical-stage biotechnology company that researches and develops therapies derived from biological science, specifically leveraging natural killer T (NKT) cell biology. Its lead programs, such as GRI-0621 for idiopathic pulmonary fibrosis and GRI-0803 for type 1 diabetes, are focused on modulating immune responses through biologic-based drug discovery.
MBIO
2nd
Mustang Bio
$3.43Mn
0.51
-1.92%
-67.52%
The company also develops MB-108, an oncolytic virus therapy based on a modified herpes simplex virus type 1 (HSV-1), which falls under the broader category of biological science-derived therapies.
LEXX
Lexaria Bioscience
$3.39Mn
3.22
-1.83%
-78.15%
Lexaria Bioscience is a biotechnology company that develops the DehydraTECH drug delivery platform to enhance the bioavailability of active pharmaceutical ingredients. Its revenue model is based on licensing this biological science-based technology to partners and receiving royalties and milestone payments.
REVB
Revelation Biosciences
$3.36Mn
0.86
-3.37%
-84.97%
Revelation Biosciences is a clinical-stage company developing immunomodulatory therapies derived from biological science, specifically its proprietary Gemini platform that modulates Toll-like receptor 4. The company is focused on the research and development of biologic-based candidates for acute kidney injury (GEM AKI) and chronic kidney disease (GEM CKD).
SXTP
2nd
60 Degrees Pharmaceuticals
$3.32Mn
1.25
+6.84%
-79.71%
The firm leverages 'cutting edge biological science' to advance its pipeline and pursues collaborations and milestone payments tied to the development of new therapies for infectious diseases.
EVGN
2nd
Evogene
$3.31Mn
0.38
-9.52%
-67.80%
The company's Pharmaceutical unit specifically advances the development of novel small molecule drug candidates for human health applications, targeting neurodegenerative disorders and cancers.
AZTR
Azitra
$3.28Mn
0.17
+0.00%
-76.06%
Azitra is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically engineered proteins and topical live biotherapeutic products. Its lead candidates, such as ATR 12 and ATR 04, are based on genetically modified strains of Staphylococcus epidermidis.
MBRX
Moleculin Biotech
$3.24Mn
0.57
-5.00%
-95.32%
Moleculin Biotech is a biotechnology company focused on researching and developing novel cancer therapies, such as Annamycin and the WP1066 portfolio. Its revenue model consists of licensing agreements, milestone payments, and research collaborations, which is characteristic of clinical-stage biotech developers.
PBM
Psyence Biomedical
$3.13Mn
5.66
+1.80%
-95.46%
Psyence Biomedical is a biotechnology company developing therapies derived from biological science, specifically natural psilocybin products for mental health conditions. The company is in the development stage with no commercial revenue, focusing on clinical assets like PEX010.
CVM
Cel Sci
$3.11Mn
1.72
+1.18%
-80.50%
CEL-SCI is a biotechnology company developing therapies derived from biological science, specifically Multikine, which is described as a biological medicinal immunotherapy comprised of natural cytokines and small biological molecules. The company is currently in the clinical-stage of development for these biologic product candidates.
AIM
AIM ImmunoTech
$3.08Mn
0.18
-5.26%
-93.23%
AIM ImmunoTech is a biotechnology company focused on therapies derived from biological science, specifically a proprietary double-stranded RNA platform. Its lead candidate, Ampligen (rintatolimod), is a double-stranded RNA molecule being developed for anticancer and antiviral properties.
APVO
Aptevo Therapeutics
$2.71Mn
1.91
+1.06%
-92.63%
Aptevo Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically bispecific and multi-specific antibodies like mipletamig and ALG APV 527. Its revenue model consists of collaboration agreements, licensing arrangements, and milestone payments from partners such as Alligator Bioscience.
BCAB
BioAtla
$2.66Mn
1.60
+25.00%
-95.38%
BioAtla researches and develops therapies derived from biological science, specifically conditionally active biologics (CABs), monoclonal antibodies, and antibody-drug conjugates for cancer treatment. Its revenue is currently derived from collaboration and licensing agreements with pharmaceutical partners like Bristol-Myers Squibb and Context Therapeutics.
NIKI
Niki BioSolutions
$2.58Mn
4.74
+2.60%
-73.96%
Aptorum Group Limited is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic assets for oncology and infectious diseases. It utilizes proprietary platforms like the Smart-ACT® drug discovery system to advance drug candidates such as ALS-4 and SACT-1.
BIAF
2nd
bioAffinity Technologies
$2.58Mn
7.41
-6.56%
-84.80%
The company's OncoSelect® Therapeutics segment conducts research on novel cancer therapeutic approaches, including the development of topical treatments for squamous cell skin cancer.
ONCO
2nd
Onconetix
$2.49Mn
1.11
+7.77%
-99.31%
The company is described as a biotechnology company that utilizes genetics-guided biomarker discovery linked to the PI3K/PTEN pathway to develop its products.
HCWB
HCW Biologics
$2.42Mn
1.82
-5.70%
-92.10%
HCW Biologics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically fusion immunotherapeutics and multifunctional proteins using its TOBI and TRBC platforms. Its revenue is derived from biologic-focused licensing agreements, milestone payments, and royalties from partners like Wugen and TRimmune.
ELAB
PMGC Holdings
$2.33Mn
4.78
+4.60%
-99.63%
The company's biotechnology segment, Northstrive Biosciences Inc., develops biopharmaceutical product candidates such as EL-22 and EL-32, which are engineered probiotics designed for muscle preservation. These are biology-based therapies currently in clinical and preclinical development stages.
CNSP
CNS Pharmaceuticals
$2.30Mn
5.19
+5.27%
-41.62%
CNS Pharmaceuticals is explicitly described as a biotechnology company focused on developing innovative therapies for neurology and oncology. As a development-stage firm with no current revenue, it fits the H-02 profile of a biotech developer seeking to commercialize therapies derived from biological science.
BIXT
Bioxytran
$2.29Mn
0.02
+0.00%
-71.43%
Bioxytran is a clinical-stage company developing therapies derived from biological science, specifically focusing on carbohydrate drug design for glycovirology and oxygen carrier platforms. Its revenue model is based on the future sale of biologic drug candidates, licensing agreements, and royalties.
IVF
2nd
INVO Fertility
$2.13Mn
0.93
-1.06%
-97.16%
Through its NAYA Therapeutics segment, the company develops bispecific antibody therapeutics for oncology and autoimmune diseases, specifically targeting hepatocellular carcinoma and multiple myeloma.
ABPO
Abpro Holdings
$2.06Mn
0.35
-2.78%
-95.46%
Abpro Holdings is a biotechnology company that develops therapies derived from biological science, specifically bispecific and multispecific antibodies using its DiversImmune and MultiMab platforms. Its revenue is currently derived from collaboration milestone payments and equity investments from partners like Celltrion and Abpro Bio for programs such as ABP 102 and ABP 201.
SILO
Silo Pharma
$1.86Mn
1.65
-5.17%
-85.33%
Silo Pharma is a developmental stage biopharmaceutical company researching and developing therapies such as SPC15 (serotonin 4 receptor agonist) and SPU16 (CNS homing peptide). Its revenue model currently consists of license fees, milestone payments, and royalties associated with these biological drug candidates.
RNAZ
Transcode Therapeutics
$1.73Mn
1.71
+1.18%
-83.94%
TransCode Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically RNA-based therapeutics like the antisense inhibitor TTX-MC138 and the polyvalent antigen vaccine Seviprotimut-L. Its business model focuses on biology-based drug discovery and development for high-risk and advanced cancers.
JUNS
2nd
Jupiter Neurosciences
$1.67Mn
2.51
-7.04%
-98.14%
The company is a clinical-stage biopharmaceutical firm developing JOTROL™, a resveratrol-based therapy for neuroinflammation, Parkinson's disease, and Alzheimer's disease. This activity involves biological science research and clinical trials (Phase I and Phase IIa) to develop therapeutic candidates.
XRTX
XORTX Therapeutics
$1.62Mn
1.71
+1.18%
-57.04%
XORTX Therapeutics is a biotechnology company researching and developing therapies derived from biological science, specifically targeting purine and uric acid metabolism. Its pipeline includes candidates such as XRx 026 for gout and XRx 008 for autosomal dominant polycystic kidney disease, which are currently in clinical or pre-clinical development.
CRIS
Curis
$1.62Mn
0.83
+0.00%
-97.50%
Curis is a biotechnology company researching and developing emavusertib, a small molecule inhibitor for hematologic malignancies. Its revenue model is based on collaboration and licensing arrangements, including milestone payments and royalties from its partnership with Aurigene Discovery Technologies.
GOVX
GeoVax Labs
$1.60Mn
0.35
+0.00%
-97.77%
GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies, such as GEO-MVA for poxviruses and GEO-CM04S1 for COVID-19, using a Modified Vaccinia Ankara (MVA) platform. Its revenue model is based on the development and potential commercialization of these biologic candidates, as well as selective licensing and partnership arrangements.
ENLV
Enlivex
$1.58Mn
0.52
-13.33%
-96.57%
Enlivex is a biotechnology company developing Allocetra™, a macrophage reprogramming therapy designed to restore immune balance for inflammatory and degenerative conditions like osteoarthritis. The company is currently in the clinical development stage, having reported Phase I/II trial data.
BTAIQ
BioXcel Therapeutics
$1.25Mn
0.04
+0.00%
-98.47%
BioXcel is a biopharmaceutical company that develops therapies derived from biological science, including the oral innate immune activator BXCL701 for aggressive cancers. Its core business model involves using an AI platform for drug discovery and development in neuroscience and immuno-oncology.
DCOY
Decoy Therapeutics
$1.23Mn
2.31
-25.24%
-94.93%
Decoy Therapeutics is a pre-clinical biotechnology company developing peptide conjugate therapeutics using its proprietary IMP 3 ACT platform. Its business model focuses on biology-based drug discovery for infectious diseases and oncology, which aligns with the H-02 classification for biotechnology developers.
NXTS
Nexentis Technologies
$1.20Mn
1.47
+0.00%
-94.52%
The company's primary business is conducted through MitoCareX Bio Ltd, which develops drug candidates for cancer and inflammatory metabolic diseases using its proprietary MITOLINE platform. It generates revenue from licensing this platform, milestone payments, and royalties from pharmaceutical and biotechnology firms.
VIVS
2nd
VivoSim Labs
$1.15Mn
0.22
+0.00%
-92.72%
The company engages in early-stage internal drug discovery and target validation, as evidenced by its development and subsequent sale of the FXR314 program to Eli Lilly and Company.
SBFM
2nd
Sunshine Biopharma
$1.12Mn
0.82
-2.38%
-94.34%
The company has a proprietary drug development segment focusing on biological therapies, specifically the K1.1 mRNA therapeutic for liver cancer.
ALP
Alpha Compute
$980.29K
5.30
-5.02%
-4.16%
AlphaTON Capital Corp is a clinical-stage immuno-oncology company developing therapies such as adenosine receptor antagonists and invariant natural killer T cell engagers. These are biology-based drug candidates targeting cancer resistance pathways, which fits the description of biotechnology drug discovery and development.
BBLG
2nd
Bone Biologics
$905.19K
0.50
+0.00%
-79.34%
The company's core technology relies on the recombinant human protein NELL 1, which is a biologic derived from biological science used to induce bone regeneration.
AGTX
Agentix
$801.34K
0.02
+0.00%
-60.00%
Agentix is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases, specifically peripherally restricted cannabinoid receptor 1 antagonists. Its revenue model is based on the typical biotechnology pattern of future milestone payments, royalties, and licensing fees.
PPCB
Propanc Biopharma
$595.57K
0.53
-15.87%
-98.84%
Propanc Biopharma is a clinical-stage company developing therapies derived from biological science, specifically pancreatic proenzymes (trypsinogen and chymotrypsinogen) to target cancer stem cells. Its lead product candidate, PRP, and its recombinant backup compound program align with the biotechnology focus on biologics and recombinant proteins.
HLSQ
Tessera Defense & Homeland Security
$474.40K
0.46
-11.54%
—
BiomX is a clinical-stage biotechnology company developing phage-based therapies derived from biological science to treat bacterial infections. Its core business involves using a proprietary research and development platform to identify and combine phage strains for therapeutic use.
CPMV
Mosaic ImmunoEngineering
$434.53K
0.06
+0.00%
-92.21%
Mosaic ImmunoEngineering is a development-stage biotechnology company focused on researching and developing immunotherapies for cancer. It utilizes a biological platform, the cowpea mosaic virus, to stimulate immune responses to destroy tumor cells.
VBIO
Valion Bio
$365.04K
2.70
-10.89%
-96.30%
The company's primary focus is its Biologics Program, specifically the development of Entolimod, a Toll-like receptor 5 agonist, and Entolasta for acute radiation syndrome and oncology. These are biologic therapies derived from biological science, fitting the H-02 classification.
LYRA
Lyra Therapeutics
$354.98K
0.20
+566.67%
-96.86%
Lyra Therapeutics is a clinical-stage biotechnology company developing anti-inflammatory therapies, specifically the lead product candidates LYR-210 and LYR-220. Its business model is based on the research and development of biological/chemical therapies for chronic rhinosinusitis.
PPBT
Purple Biotech
$244.30K
1.49
-1.32%
-74.75%
Purple Biotech is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like CM24 and the CAPTN tri-specific antibody platform. Its business model focuses on biology-based drug discovery and development for oncology.
SLXN
Silexion Therapeutics
$171.84K
0.25
-3.85%
-99.26%
Silexion Therapeutics is a biotechnology company developing therapies derived from biological science, specifically using chemically modified small interfering RNA (siRNA) to target the KRAS oncogene. Its lead product candidate, SIL204, is a second-generation siRNA designed for patients with locally advanced pancreatic cancer.
ARTL
Artelo Biosciences
$85.67K
4.30
-5.29%
-97.28%
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting lipid signaling and the endocannabinoid system. Its product candidates, such as ART27.13 and ART26.12, are being developed for conditions like cancer-related anorexia and chemotherapy-induced peripheral neuropathy.
AAGH
America Great Health
$0.00
0.00
—
—
The company focuses on the development and commercialization of protein and peptide small-molecule drugs and anti-cancer peptide research. It generates revenue from licensing and collaboration agreements, royalties, and milestone payments tied to these biotechnology projects.
ADTX
Aditxt
$0.00
0.00
—
-100.00%
Aditxt is a biotechnology company developing therapies derived from biological science, specifically its apoptotic DNA immunotherapy platform (Adimune) and antiviral solutions (Adivir). Its revenue model includes licensing proprietary technologies and pursuing the commercialization of biologic product candidates for autoimmune diseases and infectious diseases.
AIBT
Aibotics
$0.00
0.00
—
—
Aibotics is a biotechnology company that researches and develops psychedelic-based therapies for mental health, specifically supplying active pharmaceutical ingredients like psilocybin to researchers and pharmaceutical companies.
CNBX
CNBX Pharmaceuticals
$0.00
0.00
—
—
CNBX Pharmaceuticals is a clinical-stage company developing therapies derived from biological science, specifically cannabinoid-based products like Cannabics SR and RCC-33. Its revenue model is based on potential future licensing agreements, royalties, and milestone payments from partnerships with larger pharmaceutical companies.
IOBTQ
IO Biotech
$0.00
0.00
—
-100.00%
IO Biotech is a clinical-stage biopharmaceutical company developing therapeutic cancer vaccines, such as Cylembio, derived from biological science to modulate the immune system. Its revenue model is based on the development of biologics, potential future commercial sales, and collaborations with partners like Merck.
NPHC
2nd
Nutra Pharma
$0.00
0.00
—
—
The company has a dedicated Drug Development and Research segment focused on biological science, specifically modified anticholinergic therapeutic proteins and protein-based neurotoxins for diseases like Multiple Sclerosis and ALS.
PKTX
ProtoKinetix
$0.00
0.00
—
-100.00%
ProtoKinetix is a research and development stage biotechnology company focused on the development of Anti Freeze Glycoproteins (AAGPs). The company targets the development of protein-based therapeutics for anti-aging treatments and diabetes-related therapies.
RGBP
2nd
Regen BioPharma
$0.00
0.00
—
-100.00%
The company develops therapies derived from biological science, including the dCellVax and tCellVax segments which utilize siRNA inhibitors to treat metastatic breast cancer and other tumors.
